<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">R Soc Open Sci</journal-id><journal-id journal-id-type="iso-abbrev">R Soc Open Sci</journal-id><journal-id journal-id-type="publisher-id">RSOS</journal-id><journal-id journal-id-type="hwp">royopensci</journal-id><journal-title-group><journal-title>Royal Society Open Science</journal-title></journal-title-group><issn pub-type="epub">2054-5703</issn><publisher><publisher-name>The Royal Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40191531</article-id><article-id pub-id-type="pmc">PMC11972434</article-id><article-id pub-id-type="publisher-id">rsos240720</article-id><article-id pub-id-type="doi">10.1098/rsos.240720</article-id><article-categories><subj-group subj-group-type="discipline-codes"><compound-subject><compound-subject-part content-type="code">1001</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">1001</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">1001</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="subject-codes"><compound-subject><compound-subject-part content-type="code">22</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">198</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">129</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="heading"><subject>Computer Science and Artificial Intelligence</subject></subj-group><subj-group subj-group-type="type-of-publication"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>A phenotypic drug discovery approach by latent interaction in deep learning</article-title><alt-title alt-title-type="short">A phenotypic drug discovery approach by latent interaction in deep learning</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3877-3792</contrib-id><name><surname>Yu</surname><given-names>Tat Wai Billy</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role><email>billyyu@mpu.edu.mo</email></contrib><aff id="aff1">
<label>
<sup>1</sup>
</label>
<institution-wrap><institution>Macao Polytechnic University</institution></institution-wrap>, <city>Macau SAR</city>, <country>People&#x02019;s Republic of China</country>
</aff></contrib-group><author-notes><fn fn-type="other"><p>Electronic supplementary material is available online at <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.c.7486569" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.c.7486569</ext-link>.</p></fn></author-notes><pub-date date-type="collection" publication-format="electronic"><month>10</month><year>2024</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>10</month><year>2024</year><string-date>October 23, 2024</string-date></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>10</month><year>2024</year><string-date>October 23, 2024</string-date></pub-date><volume>11</volume><issue>10</issue><elocation-id>240720</elocation-id><history>
<date date-type="received"><day>02</day><month>8</month><year>2023</year><string-date>August 2, 2023</string-date></date>
<date date-type="rev-recd"><day>13</day><month>8</month><year>2024</year><string-date>August 13, 2024</string-date></date>
<date date-type="accepted"><day>14</day><month>8</month><year>2024</year><string-date>August 14, 2024</string-date></date>
</history><permissions><copyright-statement>&#x000a9; 2024 The Author(s).</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Published by the Royal Society under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="rsos.240720.pdf"/><related-object source-id="https://www.webofscience.com/api/gateway/wos/peer-review/10.1098/rsos.240720" source-id-type="url" source-type="peer-review-report" id="ss1"/><abstract><p>Contemporary drug discovery paradigms rely heavily on binding assays about the bio-physicochemical processes. However, this dominant approach suffers from overlooked higher-order interactions arising from the intricacies of molecular mechanisms, such as those involving <italic toggle="yes">cis</italic>-regulatory elements. It introduces potential impairments and restrains the potential development of computational methods. To address this limitation, I developed a deep learning model that leverages an end-to-end approach, relying exclusively on therapeutic information about drugs. By transforming textual representations of drug and virus genetic information into high-dimensional latent representations, this method evades the challenges arising from insufficient information about binding specificities. Its strengths lie in its ability to implicitly consider complexities such as epistasis and chemical&#x02013;genetic interactions, and to handle the pervasive challenge of data scarcity. Through various modeling skills and data augmentation techniques, the proposed model demonstrates outstanding performance in out-of-sample validations, even in scenarios with unknown complex interactions. Furthermore, the study highlights the importance of chemical diversity for model training. While the method showcases the feasibility of deep learning in data-scarce scenarios, it reveals a promising alternative for drug discovery in situations where knowledge of underlying mechanisms is limited.</p></abstract><kwd-group><kwd>drug design</kwd><x xml:space="preserve">; </x><kwd>target-agnostic</kwd><x xml:space="preserve">; </x><kwd>binding sites</kwd><x xml:space="preserve">; </x><kwd>deep learning</kwd><x xml:space="preserve">; </x><kwd>latent interaction</kwd><x xml:space="preserve">; </x><kwd>phenotypic approach </kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1<x xml:space="preserve">. </x>
</label><title>Introduction</title><p>In drug development, deep learning has captivated the attention of researchers. From predicting intricate drug&#x02013;target interactions to evaluating drug&#x02013;drug similarities and beyond, the applications of deep learning present exciting frontiers in the quest for more efficient and effective pharmaceutical advancements [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Mostly, it involves exploring the chemical and molecular spaces with approaches like homology for potential drug candidates [<xref rid="B4" ref-type="bibr">4</xref>]. The advantages are speed and interoperability [<xref rid="B5" ref-type="bibr">5</xref>]. However, beneath it lies a critical challenge: the need for reliable patterns in docking specificity, structural or functional properties like in spike protein, pharmacological perturbation, and transcriptomic signature matching [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>]. The realization of docking strategy is restrained by the lack of high-quality transcriptome-wide profiling data [<xref rid="B10" ref-type="bibr">10</xref>]. Their applications necessitate reliable data from diverse fields such as pharmacological targets [<xref rid="B11" ref-type="bibr">11</xref>], physicochemical characteristics [<xref rid="B12" ref-type="bibr">12</xref>] and drug pharmacokinetics [<xref rid="B13" ref-type="bibr">13</xref>], which are usually costly.</p><p>Virus gene sequences now provide a device in rational drug design [<xref rid="B14" ref-type="bibr">14</xref>]. However, data sufficiency again becomes a concern. Say, VolSite [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>] offers promise in this pursuit, yet its development path is not without challenges. Complications such as epistasis [<xref rid="B17" ref-type="bibr">17</xref>], off-target effects, traverse regulatory networks, competition for binding [<xref rid="B18" ref-type="bibr">18</xref>], the noncoding regions [<xref rid="B19" ref-type="bibr">19</xref>], synergistic interactions [<xref rid="B20" ref-type="bibr">20</xref>] and the interactome molecular pathways [<xref rid="B21" ref-type="bibr">21</xref>] in the host and other bio-physicochemical interactions contribute to snags beyond anticipated bindings [<xref rid="B22" ref-type="bibr">22</xref>]. Understanding interactions among multiple loci proves challenging. The nonlinear dynamics within the realm of biocomplexity make it virtually impossible to anticipate all potential higher-order interactions [<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>]. It is also difficult to assay complex phenotypes at scale [<xref rid="B25" ref-type="bibr">25</xref>]. Despite employing sound strategies [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>], target-binding methods in clinical drug development are hindered by high false-positive rates [<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B31" ref-type="bibr">31</xref>].</p><p>As deep learning technology continues to evolve, models to address drug development challenges become more pertinent. To this end, this study aims to harness its transformative power in advancing the methodology. Instead of using discovered patterns in docking specificity, it devises a method that relies exclusively on the therapeutic information of drugs. Hopefully, the automatic feature extraction ability in today&#x02019;s deep learning can facilitate drug prediction. In essence, this study introduces a deep learning approach to examine the complex interactions that are otherwise impossible in a typical target-based approach.</p><sec id="s1-1"><label>1.1<x xml:space="preserve">. </x>
</label><title>Current tricks for interaction recognition</title><p>Similar unorthodox methods have emerged to bypass typical reliance on explicit binding specificity information in the literature; they only leverage other strategies. A noteworthy example of this is a network-based approach. It taps into the network proximity of drug-gene signatures [<xref rid="B32" ref-type="bibr">32</xref>]. Network-based methodologies with phylogenetic analyses can also quickly identify candidate drugs [<xref rid="B33" ref-type="bibr">33</xref>]; it exemplified the potency of the network-based approach in the context of coronavirus research. In short, the network-based approach demonstrates a rapid and effective strategy without the need for explicit binding specificity; however, there is room for improvement in its performance on accuracy (the discussion section will elaborate more on this).</p><p>Conversely, metabolism functions, molecular mechanisms and a considerable proportion of intracellular proteins are regulated by the genomic sequence through the modulation of gene expression. This paradigm offers a promising avenue for drug repurposing endeavours with notions in the transcriptomics-based pipeline. Through it, deep learning methods can work out solutions by automatic feature extraction. Despite the absence of explicit therapeutic targets in various diseases and biological processes, models can glean insights from both chemical structures and gene expression changes [<xref rid="B34" ref-type="bibr">34</xref>]. With extracted latent representation of chemical molecules and landmark genes, researchers markedly demonstrate the ability to predict intricate interactions [<xref rid="B2" ref-type="bibr">2</xref>] and, more specifically, binding affinity [<xref rid="B17" ref-type="bibr">17</xref>]. These methods exploit the deep learning working mechanisms without full understanding of the underlying molecular processes. This empowers researchers to unravel highly complex bio-physicochemical relationships that cannot be manifested in conventional methods.</p><p>Whole-genome analysis has repeatedly demonstrated its clinical facilitation [<xref rid="B35" ref-type="bibr">35</xref>]. In microscopic study of pathogens, it increases the power of molecular epidemiology and helps develop novel treatments and vaccines [<xref rid="B36" ref-type="bibr">36</xref>]. In macroscopic epidemiological research, it offers a reliable means to assess the extent of viral transmission [<xref rid="B37" ref-type="bibr">37</xref>]. With the accessibility of whole-genome sequencing, deep learning methods could transcend the limitations of explicit targets and empower researchers with a more comprehensive approach to understanding biological processes.</p></sec><sec id="s1-2"><label>1.2<x xml:space="preserve">. </x>
</label><title>Utilizing molecular mechanisms</title><p>There are diverse methodologies employed in virus-based treatment options. They focus on viral nucleosides, nucleotides and nucleic acids by leveraging transcriptomics, molecular docking, and the analysis of structural and functional properties [<xref rid="B38" ref-type="bibr">38</xref>]. Amidst that, this study introduces a novel approach grounded in logic of the complex interaction among viral genes and drugs. The genetic makeup shapes viruses&#x02019; structure, function and behaviour. Some replicate and control the expression, regulate and encode proteins that interact with their host cell proteins. Recognizing this pivotal role of genes, I propose a method to harness genetic information as a comprehensive summary of functional and behavioural features for in-depth deep learning analysis with the drug.</p><p>In like manner, the functionality of a drug is shaped by its chemical makeup, which can be represented by the International Chemical Identifier (InChI) [<xref rid="B39" ref-type="bibr">39</xref>]. The InChI is a text string that effectively identifies and summarizes the chemical information, including the molecular structure, bonding, isotope, stereochemistry, etc. By recognizing this representation as a source of drug information about its functionality and behaviour, we can utilize deep learning analysis to probe into its interaction with viruses.</p><p>However, the challenge lies in the extraction and transformation of the information into meaningful features for modelling the interactions. Traditional docking strategies depend on explicit means by geometric features. In contrast, the strategy here tries to extract features automatically [<xref rid="B40" ref-type="bibr">40</xref>] with proper modeling skills in deep learning. A detailed description of our approach to achieving the designated objectives will be presented in &#x000a7;&#x000a7;2.1 and 2.2.</p><p>In essence, this novel approach draws an analogy to how our ancestors discovered drugs through the observation of their effects [<xref rid="B41" ref-type="bibr">41</xref>]. This phenotypic drug discovery approach has lately been supplanted by the reductionist approach of modulating specific molecular targets of interest [<xref rid="B42" ref-type="bibr">42</xref>]. Distinct from the assumptions about specific genome regions, our target-agnostic approach bypasses functional preconceptions of introns, exons, non-coding regions, etc. Also, it makes no assumption about the functionality of specific genome regions. Instead, it uses end-to-end learning to acquire knowledge of molecular targets or even pathways implicitly. &#x000a7;2 altogether serves as a meticulous exposition of our process, wherein deep learning models are wielded to scrutinize complex interactions.</p><p>The focus of this study is on leveraging deep learning to unveil specificities, targets or mechanisms in the latent space, in which the latent space analysis approach has shown success in molecular interactions within the tumor microenvironment [<xref rid="B43" ref-type="bibr">43</xref>]. This approach harmoniously integrates reductionist concepts with the formidable capabilities of deep learning tools. This amalgamation aims to untangle the interaction intricacy based on the discovered drugs and virus genetic information. The rest of this paper presents the comprehensive strategy.</p></sec></sec><sec sec-type="materials|methods" id="s2"><label>2<x xml:space="preserve">. </x>
</label><title>Material and methods</title><p>I approach the drug&#x02013;virus problem as a supervised deep learning task. An intention is to recognize potential interactions through end-to-end learning. Nevertheless, deep learning techniques require massive data for model training but there were only 58 antiviral-drug available in the Virus Pathogen Resource (ViPR) [<xref rid="B44" ref-type="bibr">44</xref>]. This small sample size does not provide enough therapeutic cues for most deep learning models to learn. Data scarcity is an impediment. In contrast, there are more than ten thousand FDA-approved drugs (10,282). FDA approval is a decent inclusion criterion because the FDA undergoes a rigorous review process to ensure drug eligibility. It should provide guaranteed information and sufficient accessible chemical diversity for a model to learn some pharmacophores [<xref rid="B45" ref-type="bibr">45</xref>]. We can utilize this availability. A simple data augmentation technique can translate this data availability into the feasibility of deep learning analysis.</p><p>Therefore, I created negative samples using data augmentation [<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>]. Pairs of virus genes and drugs were each labelled with their compatibility, a match or a mismatch. When a drug was approved by FDA for a virus disease, the corresponding pair was considered effective for the treatment; I assigned a value of one (1) to it. For the mismatch, a pair was assigned a value of zero (0 a negative sample). However, this negative assignment might be a misjudgment, resulting in a trained model wrongly disqualifying a drug. In this setup of maximizing chemical diversity, I fabricated negative training examples with minimal repetitions to reduce potential falsely mismatched noises. This was accomplished by a data augmentation technique to enable supervised deep learning models to work on a typical binary prediction problem.</p><p>The 58 drugs served as seeds for creating an authentic drug&#x02013;virus dataset. The number of unique virus names (organism names) was 198. The model aims to predict the drug efficacy based on the textual inputs: nucleotide sequence of the virus and the drug representation. I mapped the virus names to the NCBI Viral Genomes Resource [<xref rid="B48" ref-type="bibr">48</xref>]; 775 unique assemblies of viruses were identified. I then obtained the genome sequences from GenBank. The number of unique genome sequences at the nucleotide level in FASTA representation was 1353. Long sequences of this number shall provide enough nucleotide information for the training process.</p><p>For the drug part, I used InChI instead of SMILES to represent chemical structure because it is more informative. Although SMILES are more human-readable, the InChI format separates the information about atoms and bonds. It explicitly describes the structure of a molecule and the bonding between atoms; its hierarchical layered line notation further provides information about the structural complexity. Thus, it has an advantage in dealing with complexities like isomers, isotopic distributions and more importantly the type of nomenclature that helps understand the structure of a molecule.</p><p>Despite the fact that the InChI representation provides more information about drug molecules, there were successful cases of using the SMILES representation for deep learning model to learn. For SMILES, character strings were successfully encoded by using recurrent neural networks (RNNs) as well as convolutional neural networks (CNNs). Nevertheless, good performance was contributed by the presence of repetitive, translationally invariant substrings that correspond to chemical substructures, e.g. cycles and functional groups [<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>]. On the other hand, the InChI representation has a more complex syntax that includes counting and arithmetic. Its hierarchical layers also hinder the feasibility of analyzing the text strings as plain sequences. Encoders with relatively simple RNNs and CNNs would not be able to perform. InChI layering structure demands more sophisticated deep learning architecture, like the language model, to understand it for prediction accuracy. To solve the problem, I deploy members from the seminal work of the transformer-family [<xref rid="B51" ref-type="bibr">51</xref>] to handle its language-like complication and its layering structure. &#x000a7;2.2 is dedicated to the custom-building process.</p><p>Data construction took into consideration its uncommonness of drug repurposing and practicability in training. Drugs uncovered for repurposing are rare; the arrangement of unbalanced data is inevitable. However, the rarity shall not be too extreme that it brings unnecessary technical analysis difficulties. Thus, the number of mismatches (negative samples) was roughly 12 times (12 &#x000d7;) more than the matches. To evaluate model performance, data was partitioned into three (3) pieces: training, validation and testing data. In order to preclude potential data leakage, authentic matches of an antiviral drug were exclusive in only one of the data partitions. &#x000a7;3.1 will reveal more detail. To further evaluate the potential of data leakage, results will be accompained with some drug similarity assessment to examine the reliability.</p><p>For the model to learn, the training data were of the largest proportion. It contained 208 223 drug&#x02013;virus pairs, of which 14 646 (6.9%) were authentic matches. The validation data provides the first test against unseen data, it helps to evaluate how well the model can predict results of new data, oversee the training process of potential overfitting and tune the model. It had 59 424 pairs, with 4104 authentic (6.7%). The test data examined the model prediction accuracy after the model was built. It provided a decisive real-world check of an unseen dataset to substantiate model performance. It contained 30 244 pairs, with 2591 authentic (8.4%) for ultimate out-of-sample evaluation.</p><p>In contrast to conventional methods, the inputs are simply the InChI representations of drugs and the genetic information of viruses. Deep learning models are to convert these text strings into high-dimensional latent data for the process. This approach tackles the issues of scarce data and complex biological and chemical properties. To the best of the author&#x02019;s knowledge, no previous research took this alternative path of using pure text strings as inputs and language models for the problem. Thus, I made available the datasets for other researchers to work on<xref rid="fn1" ref-type="fn">
<sup>1</sup>
</xref>. <xref rid="F1" ref-type="fig">Figure 1</xref> illustrates the framework of this study.</p><fig position="float" fig-type="figure" id="F1"><label>Figure 1<x xml:space="preserve">. </x>
</label><caption><p>The model framework. Panel (<italic toggle="yes">a</italic>) is a one-dimensional CNN-based ResNet autoencoder for the virus FASTA representation. The resulting virus digest is coloured orange. Panel (<italic toggle="yes">b</italic>) is an autoencoder for the drug InChI representation. The encoder is essentially the ETC model. Panel (<italic toggle="yes">c</italic>) shows the core model. After the stylish self-interaction search for the digest individually, a Perceiver model searches for meaningful interactive features iteratively.</p></caption><alt-text>The model framework.</alt-text><graphic xlink:href="rsos.240720.f001" position="float"/></fig><p>I used the ensemble method [<xref rid="B52" ref-type="bibr">52</xref>] to formulate and train the model in a modular way. It starts with the basic premise that we should maximize the utilization of available information on both viruses and drugs and we should tickle problems with relevant deep learning architecture. I preprocessed the inputs with pre-trained models to obtain representations before the interaction search. Model training consisted of two phases. The first phase involved learning relevant features of drugs and viruses with two independent autoencoders so that they could extract meaningful representations for reconstruction of corresponding raw inputs. These models leveraged the power of automatic feature extraction to generate drug and virus latent features. They were optimized to preserve essential chemical/genetic information so that the original entities could be reconstructed from the latent features. This phase focused on creating reliable encoding models for drugs and viruses. The encoder parts of the models can produce latent representations for inputs. &#x000a7;&#x000a7;2.1 and 2.2 will detail the process. This technique shall help circumvent the issues of over-parameterization and overfitting, and &#x000a7;3 will substantiate that. The outputs were two encoding models for drugs and viruses. They are responsible for creating latent features as digests. The second phase developed a deep learning classification model that takes the digests as inputs. It searches for interactions concerning the drugs and viruses in the latent space, then predicts the effectiveness of the drug on a virus supervised by the compatibility label (0 or 1). I applied various technical tricks and justified them based on the biochemical or genetic literature. &#x000a7;&#x000a7;2.3 and 2.4 will detail the process.</p><sec id="s2-1"><label>2.1<x xml:space="preserve">. </x>
</label><title>The virus digest</title><p>The first preprocessing module is for virus representation. Non-coding regions may regulate transcription, and its binding may affect the binding site affinity, specificity and diversity [<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>] and related cellular functions [<xref rid="B19" ref-type="bibr">19</xref>]. I used an unsupervised learning technique to process the whole genomic sequences to avoid missing out on this representation learning. The encoder module takes the virus genome in the 4-nucleobase form and converts it into a vector. The vector had 0&#x02019;s or 1&#x02019;s at the index bases. This input vectorization method allows multiple alternative representations in a nucleotide position, like for M and N.</p><p>I used an autoencoder to capture representative information and to reduce the long sequence to a shorter and more manageable length. <xref rid="F1" ref-type="fig">Figure 1<italic toggle="yes">a</italic>
</xref> depicts the autoencoder; it consists of two parts: the encoder extracts the latent features of viruses, and the decoder tries to reconstruct the original input sequence. The model learns to minimize the reconstruction errors. I selected the ResNet [<xref rid="B55" ref-type="bibr">55</xref>] because it can compress lengthy sequences, and its residual connections make weight updates more effective. This way, more layers could be stacked together for abstract learning. The ResNet model was implemented in eight blocks of process, each block consisting of two sub-blocks of one-dimensional convolution neural network (CNN) and batch normalization. Stages were connected with residual links. Its principle hidden dimension is 128, and it was trained with a batch size of 64. I also used squeeze-and-excitation optimization [<xref rid="B56" ref-type="bibr">56</xref>] for performance. It helps feature recalibration and can learn to use global information to select useful features and suppress others. It was proven effective for ResNet, while interdependencies between channels (of nucleotide bases) are unknown but crucial.</p></sec><sec id="s2-2"><label>2.2<x xml:space="preserve">. </x>
</label><title>The drug digest</title><p>Language models, which rely heavily on transformers, can learn representations of large-scale structural characterization from single protein sequences [<xref rid="B47" ref-type="bibr">47</xref>]. I leveraged this ability of transformers to prepare the drug pre-trained model. The InChI representation is similar to language and has a hierarchical structure. InChI allows encoding with different levels of granularity (a representation can include or exclude stereochemical, isotopic and tautomeric information [<xref rid="B39" ref-type="bibr">39</xref>]). However, with this complex structure of InChI (unlike SMILES), relatively simple RNNs and CNNs would not be able to perform.</p><p>Recent development of deep learning in natural language processing (NLP) enables effective &#x02018;understanding&#x02019; of such human-readable textual input (for example [<xref rid="B57" ref-type="bibr">57</xref>]). Nevertheless, regular transformers in conventional NLP models are less capable of understanding when the text comprises some hierarchical structure; fortunately, the extended transformer construction (ETC) model is designed to handle the challenge of encoding structured text [<xref rid="B58" ref-type="bibr">58</xref>]. It can extract meaningful molecular descriptors in the form of latent molecular representations for structures without the need for additional or explicit labels. As regularly practised, I engineered the InChI input into several layers to enhance its understanding about the textual description. As shown in <xref rid="F1" ref-type="fig">figure 1<italic toggle="yes">b</italic>
</xref>, the most basic layer was the <italic toggle="yes">word embedding</italic> layer. It tokenizes the chemical elements and other chemical information. Specific to InChI representation, a forward slash followed by a letter signifies the kind of information. For example, it identifies the protonation by '/p' and stereo sublayer by '/s'; this information is stored in the <italic toggle="yes">type embedding</italic> layer. The position embedding is a distinctive design for relative attention in the ETC model. Coupled with its <italic toggle="yes">relative position encoding</italic>, it can effectively capture complex hierarchical structures in the InChI representation. For numeric information, the number token explicitly identifies it and the <italic toggle="yes">category embedding</italic> signifies that it is a number. An advantage of this setting is that it imposes no conflict with the ETC hierarchical attention mechanism. The training of this autoencoder also followed well-regarded randomly masked words pre-training strategy [<xref rid="B59" ref-type="bibr">59</xref>], so as to predict the original word based on the context. The ETC model was implemented with six transformer layers, each with two attention heads and model hidden dimension of 128, resulting in a model depth of 64. This is the dimensionality used for the individual attention heads. The inner dimension of the feedforward neural network (FNN) is 512. For the training, the masking proportion was 10% and the batch size was 64.</p></sec><sec id="s2-3"><label>2.3<x xml:space="preserve">. </x>
</label><title>Self-association</title><p>Before examining drug&#x02013;virus interactions, I developed a scheme to handle potential self-association in the analysis context. For the gene part, the scheme considers the functional nucleotide motifs, regulatory sequences, self-complementary sequences, secondary structures, etc. Non-coding regions may also affect gene expression by binding to transcription factors, resulting in the activation or repression of transcription. The scheme should consider all of the above at a genome-wide scale, but without the conventional binding and gene expression information. To detect object bounds and objectness, I applied an object detection method with the region proposal network (RPN) [<xref rid="B60" ref-type="bibr">60</xref>]. This proven technique works well with the attention mechanisms that we will use in the cross-interaction search in the subsequent analysis phase. For the RPN, there were two layers of one-dimensional convolution networks, both with hidden dimensions of 128. The first layer was of kernel size of 3 and the other of 1, in between them was a unified (batch) normalization and (ReLU) activation layer. After this were two self-attention layers with hidden dimension of 128 in both the query and the value channels. <xref rid="F1" ref-type="fig">Figure 1<italic toggle="yes">c</italic>
</xref> shows the schematics of the analysis.</p><p>Similar self-association is also present in the drug part. It can be the modulation of physicochemical properties or the mechanisms of drug solubilization [<xref rid="B61" ref-type="bibr">61</xref>]. The InChI representation input is multifarious; without prior information on possible self-interaction, I adopted a gating mechanism to skip over unused components [<xref rid="B62" ref-type="bibr">62</xref>]. It enables high performance in a wide range of scenarios for unused parts and provides efficiency and flexibility to apply non-linear processing only where needed. The implementation of this gated residual network followed the standard, the first layer was a linear FNN. The second was a simple activation layer with an exponential linear unit (ELU). The third layer was again a linear FNN. The last was a so-called gating layer made up of two time distributed wrapped dense layers and multiplying layers with a dropout rate of 15%. All intermediate layers had hidden dimensions of 512 and the output dimension was 128.</p><p>In the context of the drug&#x02013;virus interactions, <italic toggle="yes">cis</italic>-regulatory elements, such as promoters, enhancers and silencers, regulate the transcription of nearby genes and are likely to complicate the biochemical processes. Both local and global contexts should matter for modelling dependencies among inputs. A deep learning technique strives to address this complex combinatorial scenario. Inspired by estimating interactions between pairs of gene features in studying regulatory DNA sequences [<xref rid="B63" ref-type="bibr">63</xref>], I utilized context-aware self-attention [<xref rid="B64" ref-type="bibr">64</xref>]. This self-attention is a proven technique to capture local and global contexts. This scheme efficaciously probed potential self-interactions of modeling both short- and long-term dependencies. <xref rid="F1" ref-type="fig">Figure 1<italic toggle="yes">c</italic>
</xref> shows the schematics of using context-aware self-attention.</p></sec><sec id="s2-4"><label>2.4<x xml:space="preserve">. </x>
</label><title>Cross-interaction search</title><p>Putative drug&#x02013;gene interactions only indicate binding potentials; they do not always guarantee drug effectiveness [<xref rid="B65" ref-type="bibr">65</xref>]. Similarly, the absence of interactions at certain gene loci or codons does not imply that they are irrelevant to drug efficacy. Other factors may also complicate the bio-physicochemical interactions besides the binding specificities. For example, a drug can affect gene expression levels [<xref rid="B66" ref-type="bibr">66</xref>,<xref rid="B67" ref-type="bibr">67</xref>], and there are also issues related to overlooked exons, hidden binding pockets [<xref rid="B68" ref-type="bibr">68</xref>], functions of recoded stop codons or regulators [<xref rid="B69" ref-type="bibr">69</xref>] and structural entanglement factors [<xref rid="B70" ref-type="bibr">70</xref>]. The combinatorial relationship of the binding specificities is difficult to capture. I adopted the Perceiver mechanism [<xref rid="B71" ref-type="bibr">71</xref>] to learn higher-order interactions based on the digests and preprocesses that contain high-level drug and gene self-associations in the latent space, <xref rid="F1" ref-type="fig">figure 1<italic toggle="yes">c</italic>
</xref>. It alternated between cross-attention and self-attention to process the mapped inputs and efficiently capture possible combinations. It hence identifies meaningful interactive features. More specifically, it aims to determine the effects of pharmacogenetic polymorphisms in the latent space by iteratively attending to all latent features. The perceiver encoder took the virus&#x02019;s part as the value and the drug&#x02019;s part as the query. It was made up of four self-attention layers, each of two attention heads and of hidden dimension of 128, which means a depth of 64. The pre-processed resultant was the mapped inputs. Afterward, the cross-attention and self-attention units were implemented with two attention heads and a hidden dimension of 128, that is again a depth of 64.</p><p>Since there were no labelled segments of genes and drugs in the interaction, I used an adaptive pooling layer, AutoPool, to preserve the temporally dynamic predictions in the pooling process. This modification is a proven technique to detect weakly labelled sound annotation [<xref rid="B72" ref-type="bibr">72</xref>], which is a characteristic that fits our iterative search for latent features in the sparse and unknown interaction in long sequences. Another minor but technically important issue was that the data contained observations distant from one another, especially with the mismatches of drugs. A model should be aware of the magnitudes of the differences between the current samples and the previously seen training examples [<xref rid="B73" ref-type="bibr">73</xref>]. Bayesian approaches would be the best candidate to handle such uncertainties; however, they require another framework on Bayesian neural networks. That would demand excessive computational and memory requirements. For performance concerns, I used a Gaussian Process Classification Head based on the spectral-normalized neural Gaussian process (SNGP) [<xref rid="B74" ref-type="bibr">74</xref>]. It introduced a simple but high-quality uncertainty estimation method to handle the classification problem by adding a spectral normalization during training.</p><p>Deep learning models may not learn efficiently from class-imbalance data. To ensure that the training process was not affected by distribution variability, I replaced the standard cross-entropy with a label-distribution-aware margin (LDAM) loss in the training process [<xref rid="B75" ref-type="bibr">75</xref>]. It improves the generalization error of minority classes without sacrificing the ability to fit the frequent classes. I also incorporated label smoothing [<xref rid="B76" ref-type="bibr">76</xref>]. This regularization technique turns deterministic class labels into probability distributions in the model training phase. It is a popular technique to improve performance on class-imbalance data. Furthermore, multiple performance metrics were used for evaluations. The appendix details their statistical significance.</p></sec></sec><sec sec-type="results" id="s3"><label>3<x xml:space="preserve">. </x>
</label><title>Results</title><p>The proposed model&#x02019;s overall results are shown in the top row of <xref rid="T1" ref-type="table">table 1</xref>. The area under the receiver operating characteristic curve (AUC = 99.5% for the training and 98.8% for the test data partition) is high. However, AUC focuses on the relation between the true positive rate and false positive rate; a good performance might present an optimistic picture because true negatives dominate, for the unbalanced datasets that we have. <xref rid="F2" ref-type="fig">Figure 2</xref> presents both the receiver operating characteristic (ROC) and precision&#x02013;recall (PR) curves side-by-side; they together scrutinize the model&#x02019;s effectiveness and strength. The colour of the lines indicates the data partitions and models that they represent. As anticipated, both models, with and without pre-training, perform well on the training data partition (the green and the light blue lines in both the ROC and PR curves).</p><table-wrap position="float" id="T1"><label>Table 1<x xml:space="preserve">. </x>
</label><caption><p>Model performance and assessment of the refinements. Evaluations show performance degradation in the absence of specific refinements.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">purpose</th><th align="left" valign="top" rowspan="1" colspan="1">trick</th><th align="left" valign="top" rowspan="1" colspan="1">alternative</th><th align="left" valign="top" rowspan="1" colspan="1">data partition</th><th align="left" valign="top" rowspan="1" colspan="1">AUC</th><th align="left" valign="top" rowspan="1" colspan="1">accuracy</th><th align="left" valign="top" rowspan="1" colspan="1">precision</th><th align="left" valign="top" rowspan="1" colspan="1">recall</th><th align="left" valign="top" rowspan="1" colspan="1">F1 score</th><th align="left" valign="top" rowspan="1" colspan="1">MCC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">full model with all the tricks to handle relevant issues</td><td align="left" valign="top" rowspan="3" colspan="1">including all the tricks listed below</td><td align="left" valign="top" rowspan="3" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">99.6%</td><td align="left" valign="top" rowspan="1" colspan="1">95.9%</td><td align="left" valign="top" rowspan="1" colspan="1">98.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.969</td><td align="left" valign="top" rowspan="1" colspan="1">0.967</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">99.8%</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">95.4%</td><td align="left" valign="top" rowspan="1" colspan="1">98.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.967</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">98.8%</td><td align="left" valign="top" rowspan="1" colspan="1">99.6%</td><td align="left" valign="top" rowspan="1" colspan="1">96.9%</td><td align="left" valign="top" rowspan="1" colspan="1">98.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td><td align="left" valign="top" rowspan="1" colspan="1">0.975</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">representative and effective feature extraction</td><td align="left" valign="top" rowspan="3" colspan="1">pretraining with autoencoders</td><td align="left" valign="top" rowspan="3" colspan="1">encoder not pretrained</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">99.9%</td><td align="left" valign="top" rowspan="1" colspan="1">99.3%</td><td align="left" valign="top" rowspan="1" colspan="1">93.3%</td><td align="left" valign="top" rowspan="1" colspan="1">96.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.949</td><td align="left" valign="top" rowspan="1" colspan="1">0.945</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">60.5%</td><td align="left" valign="top" rowspan="1" colspan="1">95.4%</td><td align="left" valign="top" rowspan="1" colspan="1">84.5%</td><td align="left" valign="top" rowspan="1" colspan="1">40.4%</td><td align="left" valign="top" rowspan="1" colspan="1">0.547</td><td align="left" valign="top" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">98.3%</td><td align="left" valign="top" rowspan="1" colspan="1">94.4%</td><td align="left" valign="top" rowspan="1" colspan="1">87.8%</td><td align="left" valign="top" rowspan="1" colspan="1">40.9%</td><td align="left" valign="top" rowspan="1" colspan="1">0.558</td><td align="left" valign="top" rowspan="1" colspan="1">0.577</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">object bounds and objectness in genes</td><td align="left" valign="top" rowspan="3" colspan="1">region proposal network</td><td align="left" valign="top" rowspan="3" colspan="1">absence of the trick</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">96.5%</td><td align="left" valign="top" rowspan="1" colspan="1">99.1%</td><td align="left" valign="top" rowspan="1" colspan="1">93.0%</td><td align="left" valign="top" rowspan="1" colspan="1">93.6%</td><td align="left" valign="top" rowspan="1" colspan="1">0.933</td><td align="left" valign="top" rowspan="1" colspan="1">0.928</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">87.0%</td><td align="left" valign="top" rowspan="1" colspan="1">97.9%</td><td align="left" valign="top" rowspan="1" colspan="1">94.2%</td><td align="left" valign="top" rowspan="1" colspan="1">74.3%</td><td align="left" valign="top" rowspan="1" colspan="1">0.831</td><td align="left" valign="top" rowspan="1" colspan="1">0.827</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">97.4%</td><td align="left" valign="top" rowspan="1" colspan="1">99.3%</td><td align="left" valign="top" rowspan="1" colspan="1">96.2%</td><td align="left" valign="top" rowspan="1" colspan="1">95.1%</td><td align="left" valign="top" rowspan="1" colspan="1">0.957</td><td align="left" valign="top" rowspan="1" colspan="1">0.953</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">skipping over unused components in drugs</td><td align="left" valign="top" rowspan="3" colspan="1">gating mechanism</td><td align="left" valign="top" rowspan="3" colspan="1">absence of the trick</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">98.5%</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">95.4%</td><td align="left" valign="top" rowspan="1" colspan="1">97.4%</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td><td align="left" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">93.1%</td><td align="left" valign="top" rowspan="1" colspan="1">98.8%</td><td align="left" valign="top" rowspan="1" colspan="1">95.4%</td><td align="left" valign="top" rowspan="1" colspan="1">86.4%</td><td align="left" valign="top" rowspan="1" colspan="1">0.907</td><td align="left" valign="top" rowspan="1" colspan="1">0.901</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">98.8%</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">96.5%</td><td align="left" valign="top" rowspan="1" colspan="1">98.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.973</td><td align="left" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">capturing local and global contexts</td><td align="left" valign="top" rowspan="3" colspan="1">self-attention</td><td align="left" valign="top" rowspan="3" colspan="1">absence of the trick</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">98.8%</td><td align="left" valign="top" rowspan="1" colspan="1">99.6%</td><td align="left" valign="top" rowspan="1" colspan="1">96.4%</td><td align="left" valign="top" rowspan="1" colspan="1">97.9%</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.969</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">74.6%</td><td align="left" valign="top" rowspan="1" colspan="1">95.9%</td><td align="left" valign="top" rowspan="1" colspan="1">84.7%</td><td align="left" valign="top" rowspan="1" colspan="1">49.9%</td><td align="left" valign="top" rowspan="1" colspan="1">0.628</td><td align="left" valign="top" rowspan="1" colspan="1">0.631</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">89.2%</td><td align="left" valign="top" rowspan="1" colspan="1">97.5%</td><td align="left" valign="top" rowspan="1" colspan="1">90.4%</td><td align="left" valign="top" rowspan="1" colspan="1">79.2%</td><td align="left" valign="top" rowspan="1" colspan="1">0.844</td><td align="left" valign="top" rowspan="1" colspan="1">0.833</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">temporally dynamic predictions</td><td align="left" valign="top" rowspan="3" colspan="1">adaptive pooling layer</td><td align="left" valign="top" rowspan="3" colspan="1">absence of the trick</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">98.4%</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">96.2%</td><td align="left" valign="top" rowspan="1" colspan="1">97.1%</td><td align="left" valign="top" rowspan="1" colspan="1">0.967</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">89.6%</td><td align="left" valign="top" rowspan="1" colspan="1">98.4%</td><td align="left" valign="top" rowspan="1" colspan="1">97.0%</td><td align="left" valign="top" rowspan="1" colspan="1">79.4%</td><td align="left" valign="top" rowspan="1" colspan="1">0.873</td><td align="left" valign="top" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Test data</td><td align="left" valign="top" rowspan="1" colspan="1">98.7%</td><td align="left" valign="top" rowspan="1" colspan="1">99.6%</td><td align="left" valign="top" rowspan="1" colspan="1">97.7%</td><td align="left" valign="top" rowspan="1" colspan="1">97.7%</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td><td align="left" valign="top" rowspan="1" colspan="1">0.975</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">uncertainty estimation</td><td align="left" valign="top" rowspan="3" colspan="1">gaussian process classification head (SNGP)</td><td align="left" valign="top" rowspan="3" colspan="1">absence of the trick</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">96.9%</td><td align="left" valign="top" rowspan="1" colspan="1">99.2%</td><td align="left" valign="top" rowspan="1" colspan="1">93.8%</td><td align="left" valign="top" rowspan="1" colspan="1">94.2%</td><td align="left" valign="top" rowspan="1" colspan="1">0.940</td><td align="left" valign="top" rowspan="1" colspan="1">0.935</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">96.0%</td><td align="left" valign="top" rowspan="1" colspan="1">99.1%</td><td align="left" valign="top" rowspan="1" colspan="1">93.9%</td><td align="left" valign="top" rowspan="1" colspan="1">92.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.932</td><td align="left" valign="top" rowspan="1" colspan="1">0.927</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">99.0%</td><td align="left" valign="top" rowspan="1" colspan="1">99.4%</td><td align="left" valign="top" rowspan="1" colspan="1">95.1%</td><td align="left" valign="top" rowspan="1" colspan="1">98.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.968</td><td align="left" valign="top" rowspan="1" colspan="1">0.965</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">generalization error of minority classes, with the ability to fit the frequent class</td><td align="left" valign="top" rowspan="3" colspan="1">label-distribution-aware margin (LDAM)</td><td align="left" valign="top" rowspan="3" colspan="1">standard cross-entropy</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">98.3%</td><td align="left" valign="top" rowspan="1" colspan="1">99.5%</td><td align="left" valign="top" rowspan="1" colspan="1">95.7%</td><td align="left" valign="top" rowspan="1" colspan="1">96.9%</td><td align="left" valign="top" rowspan="1" colspan="1">0.963</td><td align="left" valign="top" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">92.1%</td><td align="left" valign="top" rowspan="1" colspan="1">98.7%</td><td align="left" valign="top" rowspan="1" colspan="1">95.5%</td><td align="left" valign="top" rowspan="1" colspan="1">84.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.897</td><td align="left" valign="top" rowspan="1" colspan="1">0.892</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">99.1%</td><td align="left" valign="top" rowspan="1" colspan="1">99.6%</td><td align="left" valign="top" rowspan="1" colspan="1">96.3%</td><td align="left" valign="top" rowspan="1" colspan="1">98.6%</td><td align="left" valign="top" rowspan="1" colspan="1">0.974</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">regularization for class-imbalance data</td><td align="left" valign="top" rowspan="3" colspan="1">label smoothing</td><td align="left" valign="top" rowspan="3" colspan="1">no label smoothing</td><td align="left" valign="top" rowspan="1" colspan="1">training data</td><td align="left" valign="top" rowspan="1" colspan="1">97.1%</td><td align="left" valign="top" rowspan="1" colspan="1">99.3%</td><td align="left" valign="top" rowspan="1" colspan="1">95.5%</td><td align="left" valign="top" rowspan="1" colspan="1">94.6%</td><td align="left" valign="top" rowspan="1" colspan="1">0.950</td><td align="left" valign="top" rowspan="1" colspan="1">0.947</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">validation data</td><td align="left" valign="top" rowspan="1" colspan="1">91.2%</td><td align="left" valign="top" rowspan="1" colspan="1">98.5%</td><td align="left" valign="top" rowspan="1" colspan="1">95.6%</td><td align="left" valign="top" rowspan="1" colspan="1">82.7%</td><td align="left" valign="top" rowspan="1" colspan="1">0.887</td><td align="left" valign="top" rowspan="1" colspan="1">0.882</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">test data</td><td align="left" valign="top" rowspan="1" colspan="1">97.6%</td><td align="left" valign="top" rowspan="1" colspan="1">99.3%</td><td align="left" valign="top" rowspan="1" colspan="1">96.7%</td><td align="left" valign="top" rowspan="1" colspan="1">95.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.961</td><td align="left" valign="top" rowspan="1" colspan="1">0.958</td></tr></tbody></table></table-wrap><fig position="float" fig-type="figure" id="F2"><label>Figure 2<x xml:space="preserve">. </x>
</label><caption><p>Model performance curves. Panel (<italic toggle="yes">a</italic>) presents the receiver operating characteristic (ROC) curves, which show how sensitivity (TPR) and sensitivity (PR) vary with the threshold. Panel (<italic toggle="yes">b</italic>) presents the precision&#x02013;recall (PR) curves, which examine the model&#x02019;s ability to find those minority observations.</p></caption><alt-text>Model performance curves.</alt-text><graphic xlink:href="rsos.240720.f002" position="float"/></fig><p>Nevertheless, while deep learning models are prone to overfitting, we need to assess the performance of other data partitions. For instance, the model without pre-training seems to perform well on the testing data (the yellow line on sensitivity, <xref rid="F2" ref-type="fig">figure 2<italic toggle="yes">a</italic>
</xref>). However, its PR curve (the yellow line in <xref rid="F2" ref-type="fig">figure 2<italic toggle="yes">b</italic>
</xref>), which accounts for the potential inflation in the false positive rate (FPR), shows that the good performance on ROC is a trade-off. It just incorrectly generated more positive predictive values. Thus, the PR curves help us evaluate the models&#x02019; ability to correctly predict the minority, which are the authentic matches. The overfitting phenomenon is more noticeable in the performance for validation data, which contains a greater number of observations for evaluation. Both the ROC and PR curves (the violet lines) show that the model without pretraining cannot perform as well as the model with pretraining (the blue lines). After all, by comparing the areas under the curves, both ROC and PR curves agree that the model with pre-trained encoders performed better. To illustrate the prediction of drug-virus interaction concerning these two models, a electronic supplementary material, table S1, was created. It shows that, for the proposed model, the true positive rate is high (over 98.0% for all datasets), yet the true negative rate is even higher (99.7% for all datasets). The model is more capable in scrutinizing and disqualifying a drug than in confirming its effectiveness. On the other extreme, it illustrates that an alternative model, which was without pre-trained encoder, was not able to rediscover a drug&#x02019;s effectiveness but was only good at disqualifying a drug when it was with an irrelevant virus.</p><p>Looking into the prediction ability for drug discovery, <xref rid="T2" ref-type="table">table 2</xref> presents the subset result on FDA-approved antiviral drugs. While authentic matches of a drug were exclusive in only one of the data partitions, the model correctly rediscovered 29 out of 40 approved antiviral drugs in the training data, shown in the upper half of <xref rid="T2" ref-type="table">table 2</xref>. The remaining 11 drugs had too few observations for the model to learn in the training process: Idoxuridine, Penciclovir, Trifluridine and Valaciclovir had only four authentic matches each. Famciclovir and Aciclovir had 6; Foscarnet had 8; Vidarabine had 10; Entecavir, Adefovir Dipivoxil and Telbivudine had 35 matches each. For the 11 drugs in the validation data, the trained model correctly rediscovered nine of them. For the seven authentic drugs in the test data, the trained model correctly rediscovered six of them, missing Valganciclovir. Apart from those unsuccessful cases, most recall values were high (over 0.93), except for Boceprevir, Ledipasvir and Ombitasvir. These three drugs might share some but not all bio-physicochemical characteristics or molecular pathology with other drugs in the training data.</p><table-wrap position="float" id="T2"><label>Table 2<x xml:space="preserve">. </x>
</label><caption><p>Prediction performance on approved antiviral drugs. Model prediction result for FDA-approved antiviral drugs. There are many NAs (represented by a hyphen) in which the prediction has no true positive (TP).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="2" colspan="1"/><th align="left" valign="top" rowspan="2" colspan="2">drug</th><th align="left" valign="top" colspan="5" rowspan="1">training dataset</th><th align="left" valign="top" colspan="5" rowspan="1">validation dataset</th><th align="left" valign="top" colspan="5" rowspan="1">testing dataset</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">accuracy</th><th align="left" valign="top" rowspan="1" colspan="1">precision</th><th align="left" valign="top" rowspan="1" colspan="1">recall</th><th align="left" valign="top" rowspan="1" colspan="1">F1 score</th><th align="left" valign="top" rowspan="1" colspan="1">MCC</th><th align="left" valign="top" rowspan="1" colspan="1">accuracy</th><th align="left" valign="top" rowspan="1" colspan="1">precision</th><th align="left" valign="top" rowspan="1" colspan="1">recall</th><th align="left" valign="top" rowspan="1" colspan="1">F1 ccore</th><th align="left" valign="top" rowspan="1" colspan="1">MCC</th><th align="left" valign="top" rowspan="1" colspan="1">accuracy</th><th align="left" valign="top" rowspan="1" colspan="1">precision</th><th align="left" valign="top" rowspan="1" colspan="1">recall</th><th align="left" valign="top" rowspan="1" colspan="1">F1 score</th><th align="left" valign="top" rowspan="1" colspan="1">MCC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="21" colspan="1">training dataset</td><td align="left" valign="top" rowspan="1" colspan="1">DB00194</td><td align="left" valign="top" rowspan="1" colspan="1">Vidarabine</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00198</td><td align="left" valign="top" rowspan="1" colspan="1">Oseltamivir</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.974</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.983</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00220</td><td align="left" valign="top" rowspan="1" colspan="1">Nelfinavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.966</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.983</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00224</td><td align="left" valign="top" rowspan="1" colspan="1">Indinavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.970</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.980</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00249</td><td align="left" valign="top" rowspan="1" colspan="1">Idoxuridine</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00299</td><td align="left" valign="top" rowspan="1" colspan="1">Penciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00300</td><td align="left" valign="top" rowspan="1" colspan="1">Tenofovir disoproxil</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.968</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.984</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.984</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00426</td><td align="left" valign="top" rowspan="1" colspan="1">Famciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00432</td><td align="left" valign="top" rowspan="1" colspan="1">Trifluridine</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00442</td><td align="left" valign="top" rowspan="1" colspan="1">Entecavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00478</td><td align="left" valign="top" rowspan="1" colspan="1">Rimantadine</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00503</td><td align="left" valign="top" rowspan="1" colspan="1">Ritonavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.966</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.983</td><td align="left" valign="top" rowspan="1" colspan="1">0.978</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00529</td><td align="left" valign="top" rowspan="1" colspan="1">Foscarnet</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00558</td><td align="left" valign="top" rowspan="1" colspan="1">Zanamivir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00577</td><td align="left" valign="top" rowspan="1" colspan="1">Valaciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00649</td><td align="left" valign="top" rowspan="1" colspan="1">Stavudine</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.982</td><td align="left" valign="top" rowspan="1" colspan="1">0.976</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00718</td><td align="left" valign="top" rowspan="1" colspan="1">Adefovir dipivoxil</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00787</td><td align="left" valign="top" rowspan="1" colspan="1">Aciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00811</td><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="top" rowspan="1" colspan="1">0.976</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.931</td><td align="left" valign="top" rowspan="1" colspan="1">0.955</td><td align="left" valign="top" rowspan="1" colspan="1">0.940</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00879</td><td align="left" valign="top" rowspan="1" colspan="1">Emtricitabine</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.955</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td><td align="left" valign="top" rowspan="1" colspan="1">0.970</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00915</td><td align="left" valign="top" rowspan="1" colspan="1">Amantadine</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.957</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.978</td><td align="left" valign="top" rowspan="1" colspan="1">0.971</td><td align="left" valign="top" rowspan="1" colspan="1">0.975</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="bottom" rowspan="19" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">DB00943</td><td align="left" valign="top" rowspan="1" colspan="1">Zalcitabine</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.926</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.962</td><td align="left" valign="top" rowspan="1" colspan="1">0.950</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.967</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01048</td><td align="left" valign="top" rowspan="1" colspan="1">Abacavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.940</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.969</td><td align="left" valign="top" rowspan="1" colspan="1">0.960</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01232</td><td align="left" valign="top" rowspan="1" colspan="1">Saquinavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.982</td><td align="left" valign="top" rowspan="1" colspan="1">0.976</td><td align="left" valign="top" rowspan="1" colspan="1">0.978</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01264</td><td align="left" valign="top" rowspan="1" colspan="1">Darunavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01265</td><td align="left" valign="top" rowspan="1" colspan="1">Telbivudine</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01319</td><td align="left" valign="top" rowspan="1" colspan="1">Fosamprenavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.968</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.984</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.980</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01601</td><td align="left" valign="top" rowspan="1" colspan="1">Lopinavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB05521</td><td align="left" valign="top" rowspan="1" colspan="1">Telaprevir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.960</td><td align="left" valign="top" rowspan="1" colspan="1">0.980</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB06414</td><td align="left" valign="top" rowspan="1" colspan="1">Etravirine</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.975</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB06817</td><td align="left" valign="top" rowspan="1" colspan="1">Raltegravir</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.959</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB08864</td><td align="left" valign="top" rowspan="1" colspan="1">Rilpivirine</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.959</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB08873</td><td align="left" valign="top" rowspan="1" colspan="1">Boceprevir</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.840</td><td align="left" valign="top" rowspan="1" colspan="1">0.913</td><td align="left" valign="top" rowspan="1" colspan="1">0.915</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB08934</td><td align="left" valign="top" rowspan="1" colspan="1">Sofosbuvir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09065</td><td align="left" valign="top" rowspan="1" colspan="1">Cobicistat</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.981</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09101</td><td align="left" valign="top" rowspan="1" colspan="1">Elvitegravir</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.970</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.980</td><td align="left" valign="top" rowspan="1" colspan="1">0.983</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09102</td><td align="left" valign="top" rowspan="1" colspan="1">Daclatasvir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.946</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09183</td><td align="left" valign="top" rowspan="1" colspan="1">Dasabuvir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.946</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09297</td><td align="left" valign="top" rowspan="1" colspan="1">Paritaprevir</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.946</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09299</td><td align="left" valign="top" rowspan="1" colspan="1">Tenofovir alafenamide</td><td align="left" valign="top" rowspan="1" colspan="1">0.972</td><td align="left" valign="top" rowspan="1" colspan="1">0.959</td><td align="left" valign="top" rowspan="1" colspan="1">0.933</td><td align="left" valign="top" rowspan="1" colspan="1">0.946</td><td align="left" valign="top" rowspan="1" colspan="1">0.927</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="11" colspan="1">validation dataset</td><td align="left" valign="top" rowspan="1" colspan="1">DB00238</td><td align="left" valign="top" rowspan="1" colspan="1">Nevirapine</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00369</td><td align="left" valign="top" rowspan="1" colspan="1">Cidofovir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00495</td><td align="left" valign="top" rowspan="1" colspan="1">Zidovudine</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00625</td><td align="left" valign="top" rowspan="1" colspan="1">Efavirenz</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00705</td><td align="left" valign="top" rowspan="1" colspan="1">Delavirdine</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00900</td><td align="left" valign="top" rowspan="1" colspan="1">Didanosine</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.982</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00932</td><td align="left" valign="top" rowspan="1" colspan="1">Tipranavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.986</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01004</td><td align="left" valign="top" rowspan="1" colspan="1">Ganciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB06614</td><td align="left" valign="top" rowspan="1" colspan="1">Peramivir</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.990</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09027</td><td align="left" valign="top" rowspan="1" colspan="1">Ledipasvir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.963</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.324</td><td align="left" valign="top" rowspan="1" colspan="1">0.490</td><td align="left" valign="top" rowspan="1" colspan="1">0.559</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB09296</td><td align="left" valign="top" rowspan="1" colspan="1">Ombitasvir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.730</td><td align="left" valign="top" rowspan="1" colspan="1">0.844</td><td align="left" valign="top" rowspan="1" colspan="1">0.847</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">testing dataset</td><td align="left" valign="top" rowspan="1" colspan="1">DB00701</td><td align="left" valign="top" rowspan="1" colspan="1">Amprenavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.991</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.999</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB00709</td><td align="left" valign="top" rowspan="1" colspan="1">Lamivudine</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.985</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.952</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.933</td><td align="left" valign="top" rowspan="1" colspan="1">0.964</td><td align="left" valign="top" rowspan="1" colspan="1">0.897</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01072</td><td align="left" valign="top" rowspan="1" colspan="1">Atazanavir</td><td align="left" valign="top" rowspan="1" colspan="1">0.988</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB01610</td><td align="left" valign="top" rowspan="1" colspan="1">Valganciclovir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB04835</td><td align="left" valign="top" rowspan="1" colspan="1">Maraviroc</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.994</td><td align="left" valign="top" rowspan="1" colspan="1">0.992</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">0.987</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB06290</td><td align="left" valign="top" rowspan="1" colspan="1">Simeprevir</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.959</td><td align="left" valign="top" rowspan="1" colspan="1">0.979</td><td align="left" valign="top" rowspan="1" colspan="1">0.977</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB08930</td><td align="left" valign="top" rowspan="1" colspan="1">Dolutegravir</td><td align="left" valign="top" rowspan="1" colspan="1">0.989</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.995</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="left" valign="top" rowspan="1" colspan="1">0.997</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">0.998</td><td align="left" valign="top" rowspan="1" colspan="1">0.993</td></tr></tbody></table></table-wrap><p>Also, the generally high accuracy reveals that the model effectively discriminated mismatches. High precision and recall values reveal its ability to identify and rediscover most drugs. High F1-scores and overall prediction results reflected by MCCs help address potential concerns of the imbalanced data setup. In comparing the prediction probabilities, accuracy is mostly more than precision. It ascribes to the strong ability of the model to scrutinize a drug for unmatched viral diseases.</p><sec id="s3-1"><label>3.1<x xml:space="preserve">. </x>
</label><title>
<italic toggle="yes">Post hoc</italic> analysis</title><p>The meticulous refinements implemented had significant impacts in performance. A rigorous assessment, detailed in <xref rid="T1" ref-type="table">table 1</xref>, systematically scrutinizes the influence of each refinement across a number of metrics. Notably, the top row presents the performance of the complete proposed model. It serves as a reference for comparative analysis. Subsequent rows unveil nuanced variations achieved through the exclusion of specific refinements, colloquially referred to as the deep learning <italic toggle="yes">tricks</italic>. Of particular significance, pretraining with autoencoder emerges as a pivotal trick, as elucidated in the second row. While the model bereft of pretraining encoders exhibited marginally elevated AUC on the training data partition (99.9% versus 99.5%), its performance across other metrics, including accuracy and MCC, was conspicuously inferior. Similar deficiency extended to both validation and test datasets, indicating a pronounced overfitting issue. This observation agrees with the performance plot depicted in <xref rid="F2" ref-type="fig">figure 2</xref>. Nonetheless, sole reliance on pretraining with autoencoder was insufficient for optimal outcomes. Additional stratagems, as delineated from the third row onwards, also contributed significantly to performance enhancement. Notably, the incorporation of self-attention mechanisms and a region proposal network also yielded substantial improvements. This underscores the critical importance of considering both local and global contextual cues, as well as the precise delineation of object bounds and objectness. All these tricks matter very much in investigating the interaction.</p><p>Anyhow, the overall best performance was achieved with a complete model based on the proposed architecture. These results demonstrate the importance of using pre-training encoders, and the various techniques to avoid over-parametrization and improve generalization.</p><p>Results from the primary analysis above indicate that Ledipasvir and Ombitasvir might share some bio-physicochemical characteristics with other drugs in the training data. Therefore, their chemical diversity should play some role in facilitating the model&#x02019;s effectiveness. This section also explores the model&#x02019;s effectiveness upon chemical diversity. It suggests that chemical diversity may be an important factor for this kind of analysis, but further studies with larger and more diverse datasets are needed to confirm this finding.</p><p>To optimize the datasets for model training, we need to have drugs of high chemical diversity and structural variation. However, there are not many antiviral drugs approved by the FDA, which posited constraint in the analysis. The model accuracy depends on how drug data is split. For example, if we train the model on drugs that are chemically diverse, it might perform better. On the other hand, if a data split only contains similar structures, the model might miss important features, resulting in a biased model that cannot be generalized to other possible chemical structures for a viral disease. Therefore, performance would hence deteriorate.</p><p>To test for the sensitivity to this imperfect data, I assessed the framework again with <italic toggle="yes">k</italic>-fold cross-validation on five additional datasets. In this <italic toggle="yes">post hoc</italic> analysis, the whole training process was repeated with the same model configuration, and the 58 antiviral drugs were partitioned randomly into training, validation and test data. They shall help understand the effects of chemical diversity on the model training. <xref rid="T3" ref-type="table">Table 3</xref> shows the data split of each partition.</p><table-wrap position="float" id="T3"><label>Table 3<x xml:space="preserve">. </x>
</label><caption><p>Composition of partitions on model and cross-validation datasets. Training process of the proposed model was repeated using different partitioning of the 58 FDA-approved antiviral drugs, with five rounds of cross-validation datasets. Due to the rarity of chemical diversity and structural variation in available data, the customary deep learning practice of averaging test results over different rounds for a single performance estimate is inappropriate in this application. These cross-validation datasets demonstrate how the composition of drugs in the partitioning process (hence the chemical diversity and structural variation in the data) could affect the trained model.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">dataset</th><th align="left" valign="bottom" rowspan="1" colspan="1">model dataset</th><th align="left" valign="bottom" rowspan="1" colspan="1">CV-dataset 1</th><th align="left" valign="bottom" rowspan="1" colspan="1">CV-dataset 2</th><th align="left" valign="bottom" rowspan="1" colspan="1">CV-dataset 3</th><th align="left" valign="bottom" rowspan="1" colspan="1">CV-dataset 4</th><th align="left" valign="bottom" rowspan="1" colspan="1">CV-dataset 5</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">authentic matches in<break/>training data</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00194</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00220</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00503</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00529</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00577</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09065</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">authentic matches in<break/>validation data</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00249</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00369</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00238</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00625</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00495</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01232</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00705</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00932</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00879</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01048</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00943</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB06614</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08873</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB05521</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01264</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01601</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09102</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09297</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">authentic matches in<break/>test data</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00224</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00198</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00426</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00649</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00300</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB00709</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00299</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00558</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00701</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00432</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00900</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00718</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00442</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB01610</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01004</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01319</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00787</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00478</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB04835</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01072</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00811</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB00915</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB06290</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08864</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06817</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB06414</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB01265</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">DB08930</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09027</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09183</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09296</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB08934</td><td align="left" valign="bottom" rowspan="1" colspan="1">DB09101</td></tr></tbody></table></table-wrap><p>The model performance on the datasets in terms of ROC and PR curves is shown in <xref rid="F3" ref-type="fig">figure 3</xref>. As expected, not all the datasets could perform. The best dataset, CV-dataset 1, scored test results of 99.9% recall, 99.7% AUC, 96.1% Precision, 0.980 F1-Score and 0.978 MCC. The worst dataset, CV-dataset 5, achieved test results of 31.5% recall, 65.6% AUC, 93.8% Precision, 0.472 F1-Score and 0.521 MCC. Its trained model was overfitted to the training data. Optimizing the distribution of elements for training is critical in the partition process under the constraint of limited data, which is not unusual in medical frontiers.</p><fig position="float" fig-type="figure" id="F3"><label>Figure 3<x xml:space="preserve">. </x>
</label><caption><p>Assessing sensitivity to data with k-fold cross-validation. The sets of ROC (left) and PR curves (right) of five different cross-validation datasets demonstrate the role of chemical diversity in training the model. The purpose is to estimate the expected level of fit and errors to independent datasets. PR curves assume a threshold value that decreases from left to right. On the far left, the thresholds were so high that only a few FPs and TPs existed. While defining precision as TP / (TP + FP), a difference of 1 TP could change precision very much. In the extreme cases, the thresholds were so high that there was no TP (= 0), and the precision would be 0 (in CV-dataset 2, 3 and 5). Hence, we observe the volatility in those high-threshold regions.</p></caption><alt-text>Assessing sensitivity to data with k-fold cross-validation.</alt-text><graphic xlink:href="rsos.240720.f003" position="float"/></fig><p>The potential impact of drug similarities on our model prediction performance cannot be overlooked<xref rid="fn2" ref-type="fn">
<sup>2</sup>
</xref>. Understanding such relationships and their therapeutic mechanisms has traditionally proven instrumental in enhancing the efficiency of new drug research, particularly valuable in drug repurposing applications [<xref rid="B77" ref-type="bibr">77</xref>]. To investigate whether drug similarity might influence prediction accuracy, <xref rid="F4" ref-type="fig">figure 4</xref> presents the pairwise drug similarity based on their structural makeup [<xref rid="B78" ref-type="bibr">78</xref>]. The heatmaps depict similarity scores ranging from 0 to 1, represented by red and blue colours, respectively. The large triangles in the top-left section of the heatmaps show the similarity of drugs in training data; they play a critical role in the training process. In the model dataset&#x02019;s heatmap, some drugs exhibit significant similarity between the training and testing data, noticeable in the top-right rectangle with three blue dots. Also, there are moderately similar drugs across the training and validation data, shown in the top-centre rectangle.</p><fig position="float" fig-type="figure" id="F4"><label>Figure 4<x xml:space="preserve">. </x>
</label><caption><p>Assessing drug&#x02013;drug similarity in partitioning for the model data and CV-1 to CV-5. The heatmaps exhibit the drug-drug structural similarity (or chemical diversity) of the model dataset and the five different cross-validation datasets, corresponding to <xref rid="T3" ref-type="table">table 3</xref>. Each of them shows how similar are the distributed antiviral drugs across the training, validation and testing data. A triangle shows drugs&#x02019; similarity within a partition. A rectangle shows drugs&#x02019; similarity across partitions. The purpose is to demonstrate the role of chemical diversity in model training. Hence, we observe the power of the model to learn the drugs&#x02019; properties in the context of viral diseases without using their information on structural similarity.</p></caption><alt-text>Assessing drug-drug similarity in partitioning for the model data and CV-1 to CV-5.</alt-text><graphic xlink:href="rsos.240720.f004" position="float"/></fig><p>However, it is important to note that high drug similarity alone does not guarantee superior prediction accuracy. This is exemplified by the CV&#x02212;5 dataset&#x02019;s heatmap in <xref rid="F4" ref-type="fig">figure 4</xref>, where drugs also display similarity between the training and testing data (blue dots in the top-right rectangle), yet the model&#x02019;s performance on this dataset is the least satisfactory. We have to investigate thoroughly the issue regarding the training processes with different datasets. Comparing the training datasets (the top-left large triangles) between CV&#x02212;5 and the model data, it is evident that the model data displays greater structural dissimilarity, marked by the abundant presence of red zones. In fact, the training datasets of CV&#x02212;1 and CV&#x02212;3 exhibit more or less the same level of drug dissimilarity, suggesting their potential contribution to enhancing model performance, which is true in our results.</p><p>Notably, the training data associated with CV&#x02212;5 stands out for having the lowest degree of drug dissimilarity. As outlined in &#x000a7;2, chemical diversity is essential for a model to learn. Weak drug similarity (or high chemical diversity) in the training data facilitates model training. This <italic toggle="yes">post hoc</italic> analysis emphasizes the pivotal role of chemical diversity in the training process, affirming that the model can discern and learn about the properties of drugs even in the absence of explicit structural similarity information. This underscores the model capability to understand the functional properties of drugs related to viral diseases in the latent space.</p></sec></sec><sec sec-type="discussion" id="s4"><label>4<x xml:space="preserve">. </x>
</label><title>Discussion</title><p>This study aimed to overcome the challenge of limited knowledge on antiviral drugs by transforming the problem into a supervised classification model, with an unconventional data stratification. The model learned latent features from the InChI and FASTA representations and predicted the drug effectiveness without prior knowledge of the binding specificity. Its principle is partly similar to the gene set enrichment analysis in trying to extract biological insight from genomic data to identify groups of genes that share common biological functions or biological pathways [<xref rid="B79" ref-type="bibr">79</xref>]. However, the method presented here has merits over the conventional method by eliminating the need for explicitly identified gene sets and their expression profiles; thus, even non-coding regions could be taken into consideration in the analysis process.</p><p>From the therapeutic perspective, this study focused on the eventual outcome of a drug&#x02019;s effectiveness on viral disease. The model learned important characteristics based on the InChI and FASTA representations by a deep learning technique called end-to-end learning. However, the learned latent features remain unexplained. It inherited a limitation from deep learning, that it did not show how and what specific genes are expressed, or regulated. It only predicted the eventual outcome from its learned latent knowledge, which presumably related to the common patterns of gene expression and interactions. A drug might work in various ways: say, directly interfere with the viral pathogenicity by docking on the viral genes just as theories of thermodynamics and kinetics on binding site postulate [<xref rid="B80" ref-type="bibr">80</xref>]; or indirectly, by modifying the precondition of the cell complex or proteins, repressing the virus&#x02013;receptor interactions at the cell membranes, working on the functional properties of a virus spike protein [<xref rid="B7" ref-type="bibr">7</xref>], or interdicting the initiation of transcription process (or any stage of the gene expression) of the virus within a cell [<xref rid="B81" ref-type="bibr">81</xref>].</p><p>This study proposed a different approach from the target-based paradigm. It exploited automatic feature extraction by deep learning to avoid the difficulties of incomplete information about the actual molecular interactions, that the target-based paradigm has to cope with. Thus, this phenotypic approach could explore complex biological mechanisms that are otherwise inaccessible, due to complexities such as interferences by overlooked exons or hidden binding pockets, functions of recoded stop codons or regulators, and structural entanglement factors. Biological mechanisms were captured in the latent space. Compared to similar approaches in the literature, the network-based approach yielded around 70% accuracy for identification of well-known drug indications [<xref rid="B49" ref-type="bibr">49</xref>]. By using transcriptomic signatures or integrating chemical-chemical interactions and drug similarities to predict the anatomical therapeutic chemical drug class with machine learning methods, an accuracy around 75% can be obtained [<xref rid="B82" ref-type="bibr">82</xref>]. More recently, feature selection techniques for treatment prediction, with a random forest classifier, could yield as high as 89% in AUC [<xref rid="B83" ref-type="bibr">83</xref>]. Compared with these, the results of this study suggest that learned latent features with whole-genomic information were valuable for predicting drug effectiveness. However, the model could not rediscover some drugs when the number of cases was small. This is a common limitation of the deep learning approach [<xref rid="B84" ref-type="bibr">84</xref>]. While this approach seems feasible, it supplements the toolset in metabolomics [<xref rid="B85" ref-type="bibr">85</xref>] and calls for more comprehensive data collection in the research community. It also contributes to the literature on whole-genome analysis in the drug discovery context.</p><p>The results also provided some interesting insights into the drug&#x02013;virus interactions. The analysis strategy did not differentiate between DNA and RNA viruses when GenBank documents RNA viruses in DNA format: the base uracil (U) is represented by thymine (T). Although such difference is obsolete after RNA synthesis, single-stranded RNA chains usually fold up into more complex shapes. Nevertheless, this did not seem to affect the latent interaction search, as the folding structures did not pose a problem in the latent space. This may also imply that the drug effectiveness might be more associated with gene expression after transcription than with direct molecular binding. This supports the idea of investigating drug working mechanisms from the gene expression perspective. It also suggests that investigating molecular pathology in the latent space is viable, given sufficient structural and genetic variations and chemical diversity. The result may extend and support rational drug design.</p><p>This study also did not consider genotype or epigenetics, which may alter virus gene expression and drug interaction. The variability includes enzymes and other intra-cellular factors, like catalysts [<xref rid="B86" ref-type="bibr">86</xref>], polymerases, cytochrome inhibitors or inducers [<xref rid="B87" ref-type="bibr">87</xref>]. Despite the significant roles of accessory proteins for transcription initiation and regulation, which might be prime antiviral drug targets [<xref rid="B88" ref-type="bibr">88</xref>], the current framework disregarded those transcription factors. This study only presented a simplified picture of the drug&#x02013;virus interaction. However, the results are considerably higher in prediction accuracy when compared to similar approaches like the network-based approach or drug similarities as discussed above. It demonstrated that the simplification was acceptable. With more clinical data, future models may uncover more details about the interaction.</p><p>This study proposed an alternative approach to the popular target-based paradigm. It demonstrates the potential of using the latent features and interaction searches for phenotypic drug discovery. While this framework can be extended to study more complex biochemical and phenotypic processes, such as epigenetics or drug synergism, the <italic toggle="yes">post hoc</italic> analysis revealed how chemical diversity in data distribution could affect the model performance and generalization. This study thus highlights some limitations and implications of the phenotypic drug discovery approach that researchers should be aware of. Also, other deep learning techniques may also be applicable. This study informs future research on the feasibility and challenges of using deep learning for antiviral drug discovery.</p></sec></body><back><ack><title>Acknowledgements</title><p>The author thanks the anonymous reviewers and the editors for their patience, comments and suggestions on the manuscript. The author also thanks a certified data science professional in SAS<sup>@</sup> data mining and Oracle<sup>@</sup> database management, Mr. Frankie Fong for his assistance in the implementation and testing stages. This work is impossible without his help.</p></ack><fn-group><fn fn-type="fn" id="fn1"><label>
<sup>1</sup>
</label><p>Datasets are available at <ext-link xlink:href="https://figshare.com/s/bd39a827c4bdf2b4a7c2" ext-link-type="uri">https://figshare.com/s/bd39a827c4bdf2b4a7c2</ext-link>.</p></fn><fn fn-type="fn" id="fn2"><label>
<sup>2</sup>
</label><p>Thanks to the two anonymous reviewers who pointed out the issues of possible drug similarities.</p></fn></fn-group><sec sec-type="ethics" id="s5"><title>Ethics</title><p>This work did not require ethical approval from a human subject or animal welfare committee.</p></sec><sec sec-type="data-availability" id="s6"><title>Data accessibility</title><p>The datasets for training, together with the results that support the findings of this study are available at <ext-link xlink:href="https://figshare.com/s/bd39a827c4bdf2b4a7c2" ext-link-type="uri">https://figshare.com/s/bd39a827c4bdf2b4a7c2</ext-link> and [<xref rid="B89" ref-type="bibr">89</xref>].</p><p>Supplementary material is available online [<xref rid="B90" ref-type="bibr">90</xref>].</p></sec><sec id="s7"><title>Declaration of AI use</title><p>I have not used AI-assisted technologies in creating this article.</p></sec><sec id="s8"><title>Authors&#x02019; contributions</title><p>T.W.B.Y.: conceptualization, data curation, formal analysis, investigation, methodology, validation, writing&#x02014;original draft, writing&#x02014;review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest declaration</title><p>I declare I have no competing interests.</p></sec><sec id="s10"><title>Funding</title><p>This study did not receive any external funding support. The author covered all costs associated with the research, including the equipment and adminstration.</p></sec><ref-list><title>References</title><ref id="B1"><label>1<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Askr</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Elgeldawi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Aboul Ella</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Elshaier</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gomaa</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Hassanien</surname>
<given-names>AE</given-names>
</string-name>
</person-group>. <year>2023</year>
<article-title>Deep learning in drug discovery: an integrative review and future challenges</article-title>. <source>Artif. Intell. Rev.</source>
<volume>
<bold>56</bold>
</volume>, <fpage>5975</fpage>&#x02013;<lpage>6037</lpage>. (<pub-id pub-id-type="doi">10.1007/s10462-022-10306-1</pub-id>)<pub-id pub-id-type="pmid">36415536</pub-id>
</mixed-citation></ref><ref id="B2"><label>2<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pham</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>P</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing</article-title>. <source>Nat. Mach. Intell.</source>
<volume>
<bold>3</bold>
</volume>, <fpage>247</fpage>&#x02013;<lpage>257</lpage>. (<pub-id pub-id-type="doi">10.1038/s42256-020-00285-9</pub-id>)<pub-id pub-id-type="pmid">33796820</pub-id>
</mixed-citation></ref><ref id="B3"><label>3<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schneider</surname>
<given-names>P</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2020</year>
<article-title>Rethinking drug design in the artificial intelligence era</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>
<bold>19</bold>
</volume>, <fpage>353</fpage>&#x02013;<lpage>364</lpage>. (<pub-id pub-id-type="doi">10.1038/s41573-019-0050-3</pub-id>)<pub-id pub-id-type="pmid">31801986</pub-id>
</mixed-citation></ref><ref id="B4"><label>4<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abate</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Decherchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cavalli</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2023</year>
<article-title>Graph neural networks for conditional de novo drug design</article-title>. <source>WIREs Comput. Mol. Sci.</source>
<volume>
<bold>13</bold>
</volume>. (<pub-id pub-id-type="doi">10.1002/wcms.1651</pub-id>)</mixed-citation></ref><ref id="B5"><label>5<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leman</surname>
<given-names>JK</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2020</year>
<article-title>Macromolecular modeling and design in rosetta: recent methods and frameworks</article-title>. <source>Nat. Methods</source>
<volume>
<bold>17</bold>
</volume>, <fpage>665</fpage>&#x02013;<lpage>680</lpage>. (<pub-id pub-id-type="doi">10.1038/s41592-020-0848-2</pub-id>)<pub-id pub-id-type="pmid">32483333</pub-id>
</mixed-citation></ref><ref id="B6"><label>6<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ferreira</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dos Santos</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Oliva</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Andricopulo</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2015</year>
<article-title>Molecular docking and structure-based drug design strategies</article-title>. <source>Molecules</source>
<volume>
<bold>20</bold>
</volume>, <fpage>13384</fpage>&#x02013;<lpage>13421</lpage>. (<pub-id pub-id-type="doi">10.3390/molecules200713384</pub-id>)<pub-id pub-id-type="pmid">26205061</pub-id>
</mixed-citation></ref><ref id="B7"><label>7<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>X feng</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S wen</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</article-title>. <source>Acta Pharmacol. Sin.</source>
<volume>
<bold>41</bold>
</volume>, <fpage>1141</fpage>&#x02013;<lpage>1149</lpage>. (<pub-id pub-id-type="doi">10.1038/s41401-020-0485-4</pub-id>)<pub-id pub-id-type="pmid">32747721</pub-id>
</mixed-citation></ref><ref id="B8"><label>8<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Prinz</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Schlange</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Asadullah</surname>
<given-names>K</given-names>
</string-name>
</person-group>. <year>2011</year>
<article-title>Believe it or not: how much can we rely on published data on potential drug targets?</article-title>
<source>Nat. Rev. Drug Discov.</source>
<volume>
<bold>10</bold>
</volume>, <elocation-id>712</elocation-id>. (<pub-id pub-id-type="doi">10.1038/nrd3439-c1</pub-id>)<pub-id pub-id-type="pmid">21892149</pub-id>
</mixed-citation></ref><ref id="B9"><label>9<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Volkov</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Turk</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Drizard</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gaston-Math&#x000e9;</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rognan</surname>
<given-names>D</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>On the frustration to predict binding affinities from protein-ligand structures with deep neural networks</article-title>. <source>J. Med. Chem.</source>
<volume>
<bold>65</bold>
</volume>, <fpage>7946</fpage>&#x02013;<lpage>7958</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00487</pub-id>)<pub-id pub-id-type="pmid">35608179</pub-id>
</mixed-citation></ref><ref id="B10"><label>10<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data</article-title>. <source>Genome Biol.</source>
<volume>
<bold>20</bold>
</volume>, <fpage>18</fpage>. (<pub-id pub-id-type="doi">10.1186/s13059-019-1629-z</pub-id>)<pub-id pub-id-type="pmid">30670076</pub-id>
</mixed-citation></ref><ref id="B11"><label>11<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Castegna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gissi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Menga</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Montopoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Favia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Canton</surname>
<given-names>M</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Pharmacological targets of metabolism in disease: opportunities from macrophages</article-title>. <source>Pharmacol. Ther.</source>
<volume>
<bold>210</bold>
</volume>, <fpage>107521</fpage>. (<pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107521</pub-id>)<pub-id pub-id-type="pmid">32151665</pub-id>
</mixed-citation></ref><ref id="B12"><label>12<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>S</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery</article-title>. <source>Drug Discov. Today</source>
<volume>
<bold>25</bold>
</volume>, <fpage>150</fpage>&#x02013;<lpage>159</lpage>. (<pub-id pub-id-type="doi">10.1016/j.drudis.2019.09.023</pub-id>)<pub-id pub-id-type="pmid">31600580</pub-id>
</mixed-citation></ref><ref id="B13"><label>13<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>de Velde</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mouton</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>de Winter</surname>
<given-names>BCM</given-names>
</string-name>, <string-name>
<surname>van Gelder</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>BCP</given-names>
</string-name>
</person-group>. <year>2018</year>
<article-title>Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives</article-title>. <source>Pharmacol. Res.</source>
<volume>
<bold>134</bold>
</volume>, <fpage>280</fpage>&#x02013;<lpage>288</lpage>. (<pub-id pub-id-type="doi">10.1016/j.phrs.2018.07.005</pub-id>)<pub-id pub-id-type="pmid">30033398</pub-id>
</mixed-citation></ref><ref id="B14"><label>14<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mandal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moudgil</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mandal</surname>
<given-names>SK</given-names>
</string-name>
</person-group>. <year>2009</year>
<article-title>Rational drug design</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>
<bold>625</bold>
</volume>, <fpage>90</fpage>&#x02013;<lpage>100</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ejphar.2009.06.065</pub-id>)<pub-id pub-id-type="pmid">19835861</pub-id>
</mixed-citation></ref><ref id="B15"><label>15<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rossi</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>WKM</given-names>
</string-name>, <string-name>
<surname>Pugh</surname>
<given-names>BF</given-names>
</string-name>
</person-group>. <year>2017</year>
<article-title>Correspondence: DNA shape is insufficient to explain binding</article-title>. <source>Nat. Commun.</source>
<volume>
<bold>8</bold>
</volume>, <fpage>15643</fpage>. (<pub-id pub-id-type="doi">10.1038/ncomms15643</pub-id>)<pub-id pub-id-type="pmid">28580956</pub-id>
</mixed-citation></ref><ref id="B16"><label>16<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stepniewska-Dziubinska</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Zielenkiewicz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Siedlecki</surname>
<given-names>P</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Improving detection of protein-ligand binding sites with 3D segmentation</article-title>. <source>Sci. Rep.</source>
<volume>
<bold>10</bold>
</volume>, <elocation-id>5035</elocation-id>. (<pub-id pub-id-type="doi">10.1038/s41598-020-61860-z</pub-id>)<pub-id pub-id-type="pmid">32193447</pub-id>
</mixed-citation></ref><ref id="B17"><label>17<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Phillips</surname>
<given-names>PC</given-names>
</string-name>
</person-group>. <year>2008</year>
<article-title>Epistasis--the essential role of gene interactions in the structure and evolution of genetic systems</article-title>. <source>Nat. Rev. Genet.</source>
<volume>
<bold>9</bold>
</volume>, <fpage>855</fpage>&#x02013;<lpage>867</lpage>. (<pub-id pub-id-type="doi">10.1038/nrg2452</pub-id>)<pub-id pub-id-type="pmid">18852697</pub-id>
</mixed-citation></ref><ref id="B18"><label>18<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rajewsky</surname>
<given-names>N</given-names>
</string-name>
</person-group>. <year>2015</year>
<article-title>Competition between target sites of regulators shapes post-transcriptional gene regulation</article-title>. <source>Nat. Rev. Genet.</source>
<volume>
<bold>16</bold>
</volume>, <fpage>113</fpage>&#x02013;<lpage>126</lpage>. (<pub-id pub-id-type="doi">10.1038/nrg3853</pub-id>)<pub-id pub-id-type="pmid">25488579</pub-id>
</mixed-citation></ref><ref id="B19"><label>19<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Unfried</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Ulitsky</surname>
<given-names>I</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Substoichiometric action of long noncoding RNAs</article-title>. <source>Nat. Cell Biol.</source>
<volume>
<bold>24</bold>
</volume>, <fpage>608</fpage>&#x02013;<lpage>615</lpage>. (<pub-id pub-id-type="doi">10.1038/s41556-022-00911-1</pub-id>)<pub-id pub-id-type="pmid">35562482</pub-id>
</mixed-citation></ref><ref id="B20"><label>20<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Norman</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Horlbeck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Replogle</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jost</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gilbert</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Weissman</surname>
<given-names>JS</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Exploring genetic interaction manifolds constructed from rich single-cell phenotypes</article-title>. <source>Science</source>
<volume>
<bold>365</bold>
</volume>, <fpage>786</fpage>&#x02013;<lpage>793</lpage>. (<pub-id pub-id-type="doi">10.1126/science.aax4438</pub-id>)<pub-id pub-id-type="pmid">31395745</pub-id>
</mixed-citation></ref><ref id="B21"><label>21<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>K&#x000f6;nig</surname>
<given-names>R</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2010</year>
<article-title>Human host factors required for influenza virus replication</article-title>. <source>Nature</source>
<volume>
<bold>463</bold>
</volume>, <fpage>813</fpage>&#x02013;<lpage>817</lpage>. (<pub-id pub-id-type="doi">10.1038/nature08699</pub-id>)<pub-id pub-id-type="pmid">20027183</pub-id>
</mixed-citation></ref><ref id="B22"><label>22<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nel</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>M&#x000e4;dler</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Velegol</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hoek</surname>
<given-names>EMV</given-names>
</string-name>, <string-name>
<surname>Somasundaran</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Klaessig</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Castranova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>M</given-names>
</string-name>
</person-group>. <year>2009</year>
<article-title>Understanding biophysicochemical interactions at the nano-bio interface</article-title>. <source>Nat. Mater.</source>
<volume>
<bold>8</bold>
</volume>, <fpage>543</fpage>&#x02013;<lpage>557</lpage>. (<pub-id pub-id-type="doi">10.1038/nmat2442</pub-id>)<pub-id pub-id-type="pmid">19525947</pub-id>
</mixed-citation></ref><ref id="B23"><label>23<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Taylor</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Ehrenreich</surname>
<given-names>IM</given-names>
</string-name>
</person-group>. <year>2015</year>
<article-title>Higher-order genetic interactions and their contribution to complex traits</article-title>. <source>Trends Genet.</source>
<volume>
<bold>31</bold>
</volume>, <fpage>34</fpage>&#x02013;<lpage>40</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tig.2014.09.001</pub-id>)<pub-id pub-id-type="pmid">25284288</pub-id>
</mixed-citation></ref><ref id="B24"><label>24<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuzmin</surname>
<given-names>E</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2018</year>
<article-title>Systematic analysis of complex genetic interactions</article-title>. <source>Science</source>
<volume>
<bold>360</bold>
</volume>, <elocation-id>eaao1729</elocation-id>. (<pub-id pub-id-type="doi">10.1126/science.aao1729</pub-id>)<pub-id pub-id-type="pmid">29674565</pub-id>
</mixed-citation></ref><ref id="B25"><label>25<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dixit</surname>
<given-names>A</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2016</year>
<article-title>Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens</article-title>. <source>Cell</source>
<volume>
<bold>167</bold>
</volume>, <fpage>1853</fpage>&#x02013;<lpage>1866</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2016.11.038</pub-id>)<pub-id pub-id-type="pmid">27984732</pub-id>
</mixed-citation></ref><ref id="B26"><label>26<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Adeshina</surname>
<given-names>YO</given-names>
</string-name>, <string-name>
<surname>Deeds</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Karanicolas</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Machine learning classification can reduce false positives in structure-based virtual screening</article-title>. <source>Proc. Natl Acad. Sci. USA</source>
<volume>
<bold>117</bold>
</volume>, <fpage>18477</fpage>&#x02013;<lpage>18488</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.2000585117</pub-id>)<pub-id pub-id-type="pmid">32669436</pub-id>
</mixed-citation></ref><ref id="B27"><label>27<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bellera</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Llanos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gantner</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gavernet</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Comini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Talevi</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Can drug repurposing strategies be the solution to the COVID-19 crisis?</article-title>
<source>Expert Opin. Drug Discov.</source>
<volume>
<bold>16</bold>
</volume>, <fpage>605</fpage>&#x02013;<lpage>612</lpage>. (<pub-id pub-id-type="doi">10.1080/17460441.2021.1863943</pub-id>)<pub-id pub-id-type="pmid">33345645</pub-id>
</mixed-citation></ref><ref id="B28"><label>28<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Khanjiwala</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Khale</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prabhu</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Docking structurally similar analogues: dealing with the false-positive</article-title>. <source>J. Mol. Graph. Model.</source>
<volume>
<bold>93</bold>
</volume>, <fpage>107451</fpage>. (<pub-id pub-id-type="doi">10.1016/j.jmgm.2019.107451</pub-id>)<pub-id pub-id-type="pmid">31546174</pub-id>
</mixed-citation></ref><ref id="B29"><label>29<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>DS</given-names>
</string-name>
</person-group>. <year>2018</year>
<article-title>Recurrent neural network for predicting transcription factor binding sites</article-title>. <source>Sci. Rep.</source>
<volume>
<bold>8</bold>
</volume>, <elocation-id>15270</elocation-id>. (<pub-id pub-id-type="doi">10.1038/s41598-018-33321-1</pub-id>)<pub-id pub-id-type="pmid">30323198</pub-id>
</mixed-citation></ref><ref id="B30"><label>30<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anighoro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bajorath</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rastelli</surname>
<given-names>G</given-names>
</string-name>
</person-group>. <year>2014</year>
<article-title>Polypharmacology: challenges and opportunities in drug discovery</article-title>. <source>J. Med. Chem.</source>
<volume>
<bold>57</bold>
</volume>, <fpage>7874</fpage>&#x02013;<lpage>7887</lpage>. (<pub-id pub-id-type="doi">10.1021/jm5006463</pub-id>)<pub-id pub-id-type="pmid">24946140</pub-id>
</mixed-citation></ref><ref id="B31"><label>31<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sun</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>S</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Why 90% of clinical drug development fails and how to improve it?</article-title>
<source>Acta Pharm. Sin. B</source>
<volume>
<bold>12</bold>
</volume>, <fpage>3049</fpage>&#x02013;<lpage>3062</lpage>. (<pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.002</pub-id>)<pub-id pub-id-type="pmid">35865092</pub-id>
</mixed-citation></ref><ref id="B32"><label>32<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cheng</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Handy</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schneeweiss</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Barab&#x000e1;si</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Loscalzo</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2018</year>
<article-title>Network-based approach to prediction and population-based validation of in silico drug repurposing</article-title>. <source>Nat. Commun.</source>
<volume>
<bold>9</bold>
</volume>, <fpage>2691</fpage>. (<pub-id pub-id-type="doi">10.1038/s41467-018-05116-5</pub-id>)<pub-id pub-id-type="pmid">30002366</pub-id>
</mixed-citation></ref><ref id="B33"><label>33<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>F</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title>. <source>Cell Discov.</source>
<volume>
<bold>6</bold>
</volume>, <elocation-id>14</elocation-id>. (<pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id>)<pub-id pub-id-type="pmid">32194980</pub-id>
</mixed-citation></ref><ref id="B34"><label>34<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>C</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Feature selection revisited in the single-cell era</article-title>. <source>Genome Biol.</source>
<volume>
<bold>22</bold>
</volume>, <elocation-id>321</elocation-id>. (<pub-id pub-id-type="doi">10.1186/s13059-021-02544-3</pub-id>)<pub-id pub-id-type="pmid">34847932</pub-id>
</mixed-citation></ref><ref id="B35"><label>35<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anderson</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Vegvari</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hollingsworth</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Pi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Maddren</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Baggaley</surname>
<given-names>RF</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome</article-title>. <source>Interface Focus</source>
<volume>
<bold>11</bold>
</volume>, <elocation-id>20210008</elocation-id>. (<pub-id pub-id-type="doi">10.1098/rsfs.2021.0008</pub-id>)<pub-id pub-id-type="pmid">34956588</pub-id>
</mixed-citation></ref><ref id="B36"><label>36<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Houldcroft</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Beale</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Breuer</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2017</year>
<article-title>Clinical and biological insights from viral genome sequencing</article-title>. <source>Nat. Rev. Microbiol.</source>
<volume>
<bold>15</bold>
</volume>, <fpage>183</fpage>&#x02013;<lpage>192</lpage>. (<pub-id pub-id-type="doi">10.1038/nrmicro.2016.182</pub-id>)<pub-id pub-id-type="pmid">28090077</pub-id>
</mixed-citation></ref><ref id="B37"><label>37<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oude Munnink</surname>
<given-names>BB</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2020</year>
<article-title>Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands</article-title>. <source>Nat. Med.</source>
<volume>
<bold>26</bold>
</volume>, <fpage>1405</fpage>&#x02013;<lpage>1410</lpage>. (<pub-id pub-id-type="doi">10.1038/s41591-020-0997-y</pub-id>)<pub-id pub-id-type="pmid">32678356</pub-id>
</mixed-citation></ref><ref id="B38"><label>38<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zumla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>JFW</given-names>
</string-name>, <string-name>
<surname>Azhar</surname>
<given-names>EI</given-names>
</string-name>, <string-name>
<surname>Hui</surname>
<given-names>DSC</given-names>
</string-name>, <string-name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</string-name>
</person-group>. <year>2016</year>
<article-title>Coronaviruses - drug discovery and therapeutic options</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>
<bold>15</bold>
</volume>, <fpage>327</fpage>&#x02013;<lpage>347</lpage>. (<pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id>)<pub-id pub-id-type="pmid">26868298</pub-id>
</mixed-citation></ref><ref id="B39"><label>39<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heller</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>McNaught</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pletnev</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tchekhovskoi</surname>
<given-names>D</given-names>
</string-name>
</person-group>. <year>2015</year>
<article-title>InChI, the IUPAC international chemical identifier</article-title>. <source>J. Cheminform.</source>
<volume>
<bold>7</bold>
</volume>, <elocation-id>23</elocation-id>. (<pub-id pub-id-type="doi">10.1186/s13321-015-0068-4</pub-id>)<pub-id pub-id-type="pmid">26136848</pub-id>
</mixed-citation></ref><ref id="B40"><label>40<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zeng</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>M</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>A deep-learning system bridging molecule structure and biomedical text with comprehension comparable to human professionals</article-title>. <source>Nat. Commun.</source>
<volume>
<bold>13</bold>
</volume>, <fpage>862</fpage>. (<pub-id pub-id-type="doi">10.1038/s41467-022-28494-3</pub-id>)<pub-id pub-id-type="pmid">35165275</pub-id>
</mixed-citation></ref><ref id="B41"><label>41<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Riddle</surname>
<given-names>JM</given-names>
</string-name>
</person-group>. <year>2002</year>
<article-title>History as a tool in identifying new&#x02019; old drugs</article-title>. <source>Adv. Exp. Med. Biol.</source>
<volume>
<bold>505</bold>
</volume>, <fpage>89</fpage>&#x02013;<lpage>94</lpage>. (<pub-id pub-id-type="doi">10.1007/978-1-4757-5235-9_8</pub-id>)<pub-id pub-id-type="pmid">12083469</pub-id>
</mixed-citation></ref><ref id="B42"><label>42<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vincent</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nueda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schenone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Prunotto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mercola</surname>
<given-names>M</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Phenotypic drug discovery: recent successes, lessons learned and new directions</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>
<bold>21</bold>
</volume>, <fpage>899</fpage>&#x02013;<lpage>914</lpage>. (<pub-id pub-id-type="doi">10.1038/s41573-022-00472-w</pub-id>)<pub-id pub-id-type="pmid">35637317</pub-id>
</mixed-citation></ref><ref id="B43"><label>43<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deshpande</surname>
<given-names>A</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2023</year>
<article-title>Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces</article-title>. <source>Cell Syst.</source>
<volume>
<bold>14</bold>
</volume>, <fpage>285</fpage>&#x02013;<lpage>301</lpage>.(<pub-id pub-id-type="doi">10.1016/j.cels.2023.03.004</pub-id>)<pub-id pub-id-type="pmid">37080163</pub-id>
</mixed-citation></ref><ref id="B44"><label>44<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pickett</surname>
<given-names>BE</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2012</year>
<article-title>ViPR: an open bioinformatics database and analysis resource for virology research</article-title>. <source>Nucleic Acids Res.</source>
<volume>
<bold>40</bold>
</volume>, <fpage>D593</fpage>&#x02013;<lpage>8</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkr859</pub-id>)<pub-id pub-id-type="pmid">22006842</pub-id>
</mixed-citation></ref><ref id="B45"><label>45<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhutani</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Joshi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Raja</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bachhav</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Rajanna</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Bhutani</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>R</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>U.S. FDA approved drugs from 2015-june 2020: a perspective</article-title>. <source>J. Med. Chem.</source>
<volume>
<bold>64</bold>
</volume>, <fpage>2339</fpage>&#x02013;<lpage>2381</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01786</pub-id>)<pub-id pub-id-type="pmid">33617716</pub-id>
</mixed-citation></ref><ref id="B46"><label>46<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Staszak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Staszak</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wieszczycka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bajek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roszkowski</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tylkowski</surname>
<given-names>B</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Machine learning in drug design: use of artificial intelligence to explore the chemical structure&#x02013;biological activity relationship</article-title>. <source>WIREs Comput. Mol. Sci.</source>
<volume>
<bold>12</bold>
</volume>, <elocation-id>e1568</elocation-id>. (<pub-id pub-id-type="doi">10.1002/wcms.1568</pub-id>)</mixed-citation></ref><ref id="B47"><label>47<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lin</surname>
<given-names>Z</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2023</year>
<article-title>Evolutionary-scale prediction of atomic-level protein structure with a language model</article-title>. <source>Science</source>
<volume>
<bold>379</bold>
</volume>, <fpage>1123</fpage>&#x02013;<lpage>1130</lpage>. (<pub-id pub-id-type="doi">10.1126/science.ade2574</pub-id>)<pub-id pub-id-type="pmid">36927031</pub-id>
</mixed-citation></ref><ref id="B48"><label>48<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brister</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Ako-adjei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Blinkova</surname>
<given-names>O</given-names>
</string-name>
</person-group>. <year>2015</year>
<article-title>NCBI viral genomes resource</article-title>. <source>Nucleic Acids Res.</source>
<volume>
<bold>43</bold>
</volume>, <fpage>D571</fpage>&#x02013;<lpage>D577</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gku1207</pub-id>)<pub-id pub-id-type="pmid">25428358</pub-id>
</mixed-citation></ref><ref id="B49"><label>49<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>G&#x000f3;mez-Bombarelli</surname>
<given-names>R</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2018</year>
<article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent. Sci.</source>
<volume>
<bold>4</bold>
</volume>, <fpage>268</fpage>&#x02013;<lpage>276</lpage>. (<pub-id pub-id-type="doi">10.1021/acscentsci.7b00572</pub-id>)<pub-id pub-id-type="pmid">29532027</pub-id>
</mixed-citation></ref><ref id="B50"><label>50<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Winter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Montanari</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>No&#x000e9;</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Clevert</surname>
<given-names>DA</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations</article-title>. <source>Chem. Sci.</source>
<volume>
<bold>10</bold>
</volume>, <fpage>1692</fpage>&#x02013;<lpage>1701</lpage>. (<pub-id pub-id-type="doi">10.1039/c8sc04175j</pub-id>)<pub-id pub-id-type="pmid">30842833</pub-id>
</mixed-citation></ref><ref id="B51"><label>51<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vaswani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shazeer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Parmar</surname>
<given-names>N</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2017</year>
<article-title>Attention is all you need</article-title>. <source>Adv. Neural Inf. Process. Syst.</source>
<volume>
<bold>30</bold>
</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. (<pub-id pub-id-type="doi">10.5555/3295222.3295349</pub-id>)</mixed-citation></ref><ref id="B52"><label>52<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>JYH</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>P</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Ensemble deep learning in bioinformatics</article-title>. <source>Nat. Mach. Intell.</source>
<volume>
<bold>2</bold>
</volume>, <fpage>500</fpage>&#x02013;<lpage>508</lpage>. (<pub-id pub-id-type="doi">10.1038/s42256-020-0217-y</pub-id>)</mixed-citation></ref><ref id="B53"><label>53<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>H</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Expression, regulation, and function of exosome-derived miRNAs in cancer progression and therapy</article-title>. <source>FASEB J.</source>
<volume>
<bold>35</bold>
</volume>, <elocation-id>e21916</elocation-id>. (<pub-id pub-id-type="doi">10.1096/fj.202100294RR</pub-id>)<pub-id pub-id-type="pmid">34510546</pub-id>
</mixed-citation></ref><ref id="B54"><label>54<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhu</surname>
<given-names>X</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2022</year>
<article-title>Non-coding 7S RNA inhibits transcription via mitochondrial RNA polymerase dimerization</article-title>. <source>Cell</source>
<volume>
<bold>185</bold>
</volume>, <fpage>2309</fpage>&#x02013;<lpage>2323</lpage>.(<pub-id pub-id-type="doi">10.1016/j.cell.2022.05.006</pub-id>)<pub-id pub-id-type="pmid">35662414</pub-id>
</mixed-citation></ref><ref id="B55"><label>55<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>Q</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Efficientnet: rethinking model scaling for convolutional neural networks</article-title>. <source>Proc. Mach. Learn. Res. PMLR</source>
<fpage>6105</fpage>&#x02013;<lpage>6114</lpage>. <ext-link xlink:href="https://proceedings.mlr.press/v97/tan19a.html" ext-link-type="uri">https://proceedings.mlr.press/v97/tan19a.html</ext-link>
</mixed-citation></ref><ref id="B56"><label>56<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author">
<string-name>
<surname>Hu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>G</given-names>
</string-name>
</person-group>. <year>2018</year>
<article-title>Squeeze-and-excitation networks</article-title>. <comment>In</comment>
<conf-name>IEEE/CVF Conf. on Comp. Vis. and Patt. Rec</conf-name>, <comment>pp</comment>. <fpage>7132</fpage>&#x02013;<lpage>7141</lpage>. (<pub-id pub-id-type="doi">10.1109/CVPR.2018.00745</pub-id>)</mixed-citation></ref><ref id="B57"><label>57<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>So</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>BioBERT: a pre-trained biomedical language representation model for biomedical text mining</article-title>. <source>Bioinformatics</source>
<volume>
<bold>36</bold>
</volume>, <fpage>1234</fpage>&#x02013;<lpage>1240</lpage>. (<pub-id pub-id-type="doi">10.1093/bioinformatics/btz682</pub-id>)<pub-id pub-id-type="pmid">31501885</pub-id>
</mixed-citation></ref><ref id="B58"><label>58<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author">
<string-name>
<surname>Ainslie</surname>
<given-names>J</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2020</year>
<article-title>ETC: encoding long and structured inputs in transformers</article-title>. In <conf-name>Proc. of the 2020 Conf. on Empirical Methods in Natural Language Processing (EMNLP)</conf-name>, pp. <fpage>68</fpage>&#x02013;<lpage>284</lpage>. <publisher-loc>Stroudsburg</publisher-loc>. (<pub-id pub-id-type="doi">10.18653/v1/2020.emnlp-main.19</pub-id>)</mixed-citation></ref><ref id="B59"><label>59<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kroll</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ranjan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Engqvist</surname>
<given-names>MKM</given-names>
</string-name>, <string-name>
<surname>Lercher</surname>
<given-names>MJ</given-names>
</string-name>
</person-group>. <year>2023</year>
<article-title>A general model to predict small molecule substrates of enzymes based on machine and deep learning</article-title>. <source>Nat. Commun.</source>
<volume>
<bold>14</bold>
</volume>, <elocation-id>2787</elocation-id>. (<pub-id pub-id-type="doi">10.1038/s41467-023-38347-2</pub-id>)<pub-id pub-id-type="pmid">37188731</pub-id>
</mixed-citation></ref><ref id="B60"><label>60<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ren</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Girshick</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2017</year>
<article-title>Faster R-CNN: towards real-time object detection with region proposal networks</article-title>. <source>IEEE Trans. Pattern Anal. Mach. Intell.</source>
<volume>
<bold>39</bold>
</volume>, <fpage>1137</fpage>&#x02013;<lpage>1149</lpage>. (<pub-id pub-id-type="doi">10.1109/TPAMI.2016.2577031</pub-id>)<pub-id pub-id-type="pmid">27295650</pub-id>
</mixed-citation></ref><ref id="B61"><label>61<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schreier</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Malheiros</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>de Paula</surname>
<given-names>E</given-names>
</string-name>
</person-group>. <year>2000</year>
<article-title>Surface active drugs: self-association and interaction with membranes and surfactants physicochemical and biological aspects</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>
<bold>1508</bold>
</volume>, <fpage>210</fpage>&#x02013;<lpage>234</lpage>. (<pub-id pub-id-type="doi">10.1016/s0304-4157(00)00012-5</pub-id>)<pub-id pub-id-type="pmid">11090827</pub-id>
</mixed-citation></ref><ref id="B62"><label>62<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lim</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ar&#x00131;k</surname>
<given-names>S&#x000d6;</given-names>
</string-name>, <string-name>
<surname>Loeff</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pfister</surname>
<given-names>T</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Temporal fusion transformers for interpretable multi-horizon time series forecasting</article-title>. <source>Int. J. Forecast.</source>
<volume>
<bold>37</bold>
</volume>, <fpage>1748</fpage>&#x02013;<lpage>1764</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ijforecast.2021.03.012</pub-id>)</mixed-citation></ref><ref id="B63"><label>63<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>DS</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2021</year>
<article-title>The dynamic, combinatorial cis-regulatory lexicon of epidermal differentiation</article-title>. <source>Nat. Genet.</source>
<volume>
<bold>53</bold>
</volume>, <fpage>1564</fpage>&#x02013;<lpage>1576</lpage>. (<pub-id pub-id-type="doi">10.1038/s41588-021-00947-3</pub-id>)<pub-id pub-id-type="pmid">34650237</pub-id>
</mixed-citation></ref><ref id="B64"><label>64<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>DF</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Context-aware self-attention networks for natural language processing</article-title>. <source>Neurocomputing</source>
<volume>
<bold>458</bold>
</volume>, <fpage>157</fpage>&#x02013;<lpage>169</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neucom.2021.06.009</pub-id>)</mixed-citation></ref><ref id="B65"><label>65<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shakil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Danish Rizvi</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Greig</surname>
<given-names>NH</given-names>
</string-name>
</person-group>. <year>2023</year>
<article-title>Molecular interaction of a putative inhibitor with bacterial SHV, an enzyme associated with antibiotic resistance</article-title>. <source>R. Soc. Open Sci.</source>
<volume>
<bold>10</bold>
</volume>, <elocation-id>221458</elocation-id>. (<pub-id pub-id-type="doi">10.1098/rsos.221458</pub-id>)<pub-id pub-id-type="pmid">36778948</pub-id>
</mixed-citation></ref><ref id="B66"><label>66<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jamieson</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Pabo</surname>
<given-names>CO</given-names>
</string-name>
</person-group>. <year>2003</year>
<article-title>Drug discovery with engineered zinc-finger proteins</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>
<bold>2</bold>
</volume>, <fpage>361</fpage>&#x02013;<lpage>368</lpage>. (<pub-id pub-id-type="doi">10.1038/nrd1087</pub-id>)<pub-id pub-id-type="pmid">12750739</pub-id>
</mixed-citation></ref><ref id="B67"><label>67<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zapp</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>MR</given-names>
</string-name>
</person-group>. <year>1993</year>
<article-title>Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production</article-title>. <source>Cell</source>
<volume>
<bold>74</bold>
</volume>, <fpage>969</fpage>&#x02013;<lpage>978</lpage>. (<pub-id pub-id-type="doi">10.1016/0092-8674(93)90720-b</pub-id>)<pub-id pub-id-type="pmid">8402886</pub-id>
</mixed-citation></ref><ref id="B68"><label>68<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuzmanic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bowman</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Juarez-Jimenez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gervasio</surname>
<given-names>FL</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Investigating cryptic binding sites by molecular dynamics simulations</article-title>. <source>Acc. Chem. Res.</source>
<volume>
<bold>53</bold>
</volume>, <fpage>654</fpage>&#x02013;<lpage>661</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.accounts.9b00613</pub-id>)<pub-id pub-id-type="pmid">32134250</pub-id>
</mixed-citation></ref><ref id="B69"><label>69<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Borges</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Sachdeva</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Al-Shayeb</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Penev</surname>
<given-names>PI</given-names>
</string-name>, <string-name>
<surname>Jaffe</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Lei</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Santini</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Banfield</surname>
<given-names>JF</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Widespread stop-codon recoding in bacteriophages may regulate translation of lytic genes</article-title>. <source>Nat. Microbiol.</source>
<volume>
<bold>7</bold>
</volume>, <fpage>918</fpage>&#x02013;<lpage>927</lpage>. (<pub-id pub-id-type="doi">10.1038/s41564-022-01128-6</pub-id>)<pub-id pub-id-type="pmid">35618772</pub-id>
</mixed-citation></ref><ref id="B70"><label>70<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuzmin</surname>
<given-names>E</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2020</year>
<article-title>Exploring whole-genome duplicate gene retention with complex genetic interaction analysis</article-title>. <source>Science</source>
<volume>
<bold>368</bold>
</volume>, <elocation-id>eaaz5667</elocation-id>. (<pub-id pub-id-type="doi">10.1126/science.aaz5667</pub-id>)<pub-id pub-id-type="pmid">32586993</pub-id>
</mixed-citation></ref><ref id="B71"><label>71<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author">
<string-name>
<surname>Jaegle</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gimeno</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Brock</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Perceiver: general perception with iterative attention</article-title>. <comment>In</comment>
<conf-name>Proc. of the 38th Int. Conf. on Machine Learning</conf-name>, <comment>pp</comment>. <fpage>4651</fpage>&#x02013;<lpage>4664</lpage>. <ext-link xlink:href="https://proceedings.mlr.press/v139/jaegle21a.html" ext-link-type="uri">https://proceedings.mlr.press/v139/jaegle21a.html</ext-link>.</mixed-citation></ref><ref id="B72"><label>72<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McFee</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Salamon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bello</surname>
<given-names>JP</given-names>
</string-name>
</person-group>. <year>2018</year>
<article-title>Adaptive pooling operators for weakly labeled sound event detection</article-title>. <source>IEEE/ACM Trans. Audio. Speech. Lang. Process.</source>
<volume>
<bold>26</bold>
</volume>, <fpage>2180</fpage>&#x02013;<lpage>2193</lpage>. (<pub-id pub-id-type="doi">10.1109/TASLP.2018.2858559</pub-id>)</mixed-citation></ref><ref id="B73"><label>73<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cortes</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mohri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rostamizadeh</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2009</year>
<article-title>Learning non-linear combinations of kernels</article-title>. <source>Adv. Neural Inf. Process. Syst.</source>
<fpage>396</fpage>&#x02013;<lpage>404</lpage>. <ext-link xlink:href="https://papers.nips.cc/paper/2009/file/e7f8a7fb0b77bcb3b283af5be021448f-Paper.pdf" ext-link-type="uri">https://papers.nips.cc/paper/2009/file/e7f8a7fb0b77bcb3b283af5be021448f-Paper.pdf</ext-link>
</mixed-citation></ref><ref id="B74"><label>74<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Padhy</surname>
<given-names>S</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Simple and principled uncertainty estimation with deterministic deep learning via distance awareness</article-title>. <source>Adv. Neural Inf. Process. Syst.</source>
<volume>
<bold>33</bold>
</volume>, <fpage>7498</fpage>&#x02013;<lpage>7512</lpage>. <ext-link xlink:href="https://proceedings.neurips.cc/paper/2020/file/543e83748234f7cbab21aa0ade66565f-Paper.pdf" ext-link-type="uri">https://proceedings.neurips.cc/paper/2020/file/543e83748234f7cbab21aa0ade66565f-Paper.pdf</ext-link>
</mixed-citation></ref><ref id="B75"><label>75<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gaidon</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Arechiga</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>T</given-names>
</string-name>
</person-group>. <year>2019</year>
<article-title>Learning imbalanced datasets with label-distribution-aware margin loss</article-title>. <source>Adv. Neural Inf. Process. Syst.</source> (<pub-id pub-id-type="doi">10.5555/3454287.3454427</pub-id>)</mixed-citation></ref><ref id="B76"><label>76<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lienen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>H&#x000fc;llermeier</surname>
<given-names>E</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>From label smoothing to label relaxation</article-title>. <source>Proc. Conf. AAAI Artif. Intell.</source>
<volume>
<bold>35</bold>
</volume>, <fpage>8583</fpage>&#x02013;<lpage>8591</lpage>. (<pub-id pub-id-type="doi">10.1609/aaai.v35i10.17041</pub-id>)</mixed-citation></ref><ref id="B77"><label>77<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>FX</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>
</person-group>. <year>2021</year>
<article-title>Drug&#x02013;drug similarity measure and its applications</article-title>. <source>Brief. Bioinf.</source>
<volume>
<bold>22</bold>
</volume>, <elocation-id>bbaa265</elocation-id>. (<pub-id pub-id-type="doi">10.1093/bib/bbaa265</pub-id>)</mixed-citation></ref><ref id="B78"><label>78<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wishart</surname>
<given-names>DS</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2018</year>
<article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title>. <source>Nucleic Acids Res.</source>
<volume>
<bold>46</bold>
</volume>, <fpage>D1074</fpage>&#x02013;<lpage>D1082</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>)<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation></ref><ref id="B79"><label>79<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Subramanian</surname>
<given-names>A</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2005</year>
<article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl Acad. Sci. USA</source>
<volume>
<bold>102</bold>
</volume>, <fpage>15545</fpage>&#x02013;<lpage>15550</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>)<pub-id pub-id-type="pmid">16199517</pub-id>
</mixed-citation></ref><ref id="B80"><label>80<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Decherchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cavalli</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Thermodynamics and kinetics of drug-target binding by molecular simulation</article-title>. <source>Chem. Rev.</source>
<volume>
<bold>120</bold>
</volume>, <fpage>12788</fpage>&#x02013;<lpage>12833</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.chemrev.0c00534</pub-id>)<pub-id pub-id-type="pmid">33006893</pub-id>
</mixed-citation></ref><ref id="B81"><label>81<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Parameswaran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ernst</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Marazzi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Weirauch</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Fuxman Bass</surname>
<given-names>JI</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Human virus transcriptional regulators</article-title>. <source>Cell</source>
<volume>
<bold>182</bold>
</volume>, <fpage>24</fpage>&#x02013;<lpage>37</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.023</pub-id>)<pub-id pub-id-type="pmid">32649876</pub-id>
</mixed-citation></ref><ref id="B82"><label>82<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shukla</surname>
<given-names>R</given-names>
</string-name>
<etal>
<italic toggle="yes">et al</italic>
</etal>
</person-group>. <year>2021</year>
<article-title>Signature-based approaches for informed drug repurposing: targeting CNS disorders</article-title>. <source>Neuropsychopharmacology</source>
<volume>
<bold>46</bold>
</volume>, <fpage>116</fpage>&#x02013;<lpage>130</lpage>. (<pub-id pub-id-type="doi">10.1038/s41386-020-0752-6</pub-id>)<pub-id pub-id-type="pmid">32604402</pub-id>
</mixed-citation></ref><ref id="B83"><label>83<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ferrato</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Franke</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Kolb</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>DeRyckere</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Grahm</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Chandrasekaran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Crowgey</surname>
<given-names>EL</given-names>
</string-name>
</person-group>. <year>2023</year>
<article-title>Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and ex vivo data</article-title>. <source>Bioinform. Adv.</source>
<volume>
<bold>3</bold>
</volume>, <elocation-id>vbad034</elocation-id>. (<pub-id pub-id-type="doi">10.1093/bioadv/vbad034</pub-id>)<pub-id pub-id-type="pmid">37250111</pub-id>
</mixed-citation></ref><ref id="B84"><label>84<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nussinov</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>F</given-names>
</string-name>
</person-group>. <year>2020</year>
<article-title>Artificial intelligence in COVID-19 drug repurposing</article-title>. <source>Lancet. Dig. Health.</source>
<volume>
<bold>2</bold>
</volume>, <fpage>e667</fpage>&#x02013;<lpage>e676</lpage>. (<pub-id pub-id-type="doi">10.1016/S2589-7500(20)30192-8</pub-id>)</mixed-citation></ref><ref id="B85"><label>85<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuehnbaum</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Britz-McKibbin</surname>
<given-names>P</given-names>
</string-name>
</person-group>. <year>2013</year>
<article-title>New advances in separation science for metabolomics: resolving chemical diversity in a post-genomic era</article-title>. <source>Chem. Rev.</source>
<volume>
<bold>113</bold>
</volume>, <fpage>2437</fpage>&#x02013;<lpage>2468</lpage>. (<pub-id pub-id-type="doi">10.1021/cr300484s</pub-id>)<pub-id pub-id-type="pmid">23506082</pub-id>
</mixed-citation></ref><ref id="B86"><label>86<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miller</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Askevold</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mikula</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kohler</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Pirovich</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Weissleder</surname>
<given-names>R</given-names>
</string-name>
</person-group>. <year>2017</year>
<article-title>Nano-palladium is a cellular catalyst for in vivo chemistry</article-title>. <source>Nat. Commun.</source>
<volume>
<bold>8</bold>
</volume>, <fpage>15906</fpage>. (<pub-id pub-id-type="doi">10.1038/ncomms15906</pub-id>)<pub-id pub-id-type="pmid">28699627</pub-id>
</mixed-citation></ref><ref id="B87"><label>87<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wilkinson</surname>
<given-names>GR</given-names>
</string-name>
</person-group>. <year>2005</year>
<article-title>Drug metabolism and variability among patients in drug response</article-title>. <source>N. Engl. J. Med.</source>
<volume>
<bold>352</bold>
</volume>, <fpage>2211</fpage>&#x02013;<lpage>2221</lpage>. (<pub-id pub-id-type="doi">10.1056/NEJMra032424</pub-id>)<pub-id pub-id-type="pmid">15917386</pub-id>
</mixed-citation></ref><ref id="B88"><label>88<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Malone</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Urakova</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Snijder</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>EA</given-names>
</string-name>
</person-group>. <year>2022</year>
<article-title>Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>
<bold>23</bold>
</volume>, <fpage>21</fpage>&#x02013;<lpage>39</lpage>. (<pub-id pub-id-type="doi">10.1038/s41580-021-00432-z</pub-id>)<pub-id pub-id-type="pmid">34824452</pub-id>
</mixed-citation></ref><ref id="B89"><label>89<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name>
</person-group>. <year>2024</year>. <article-title>A phenotypic drug discovery approach by latent interaction in deep learning [Dataset]. Dryad.</article-title> (<pub-id pub-id-type="doi">10.5061/dryad.zcrjdfnnj</pub-id>)</mixed-citation></ref><ref id="B90"><label>90<x xml:space="preserve">. </x>
</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name>
</person-group>. <year>2024</year>
<article-title>Data from: A phenotypic drug discovery approach by latent interaction in deep learning. Figshare.</article-title> (<pub-id pub-id-type="doi">10.6084/m9.figshare.c.7486569</pub-id>)</mixed-citation></ref></ref-list></back></article>